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ABSTRACT 
 
Bile acids are important steroid-derived molecules essential for fat absorption in the small 
intestine. They are produced in the liver and secreted into the bile. Bile acids are transported 
by bile flow to the small intestine, where they aid the digestion of lipids. Most bile acids are 
reabsorbed in the small intestine and return to the liver through the portal vein. The whole 
recycling process is referred to as the enterohepatic circulation, during which only a small 
amount of bile acids are removed from the body via faeces. The enterohepatic circulation of 
bile acids involves the delicate coordination of a number of bile acid transporters expressed in 
the liver and the small intestine. Organic anion transporting polypeptide 1B1 (OATP1B1), 
encoded by the solute carrier organic anion transporter family, member 1B1 (SLCO1B1) 
gene, mediates the sodium independent hepatocellular uptake of bile acids. Two common 
SNPs in the SLCO1B1 gene  are  well  known  to  affect  the  transport  activity  of  OATP1B1.  
Moreover, bile acid synthesis is an important elimination route for cholesterol. Cholesterol 
??-hydroxylase (CYP7A1) is the rate-limiting enzyme of bile acid production.    
 
The aim of this thesis was to investigate the effects of SLCO1B1 polymorphism on the fasting 
plasma levels of individual endogenous bile acids and a bile acid synthesis marker, and the 
pharmacokinetics of exogenously administered ursodeoxycholic acid (UDCA). Furthermore, 
the effects of CYP7A1 genetic polymorphism and gender on the fasting plasma 
concentrations of individual endogenous bile acids and the bile acid synthesis marker were 
evaluated.  
 
Firstly, a high performance liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS) method for the determination of bile acids was developed (Study I). A retrospective 
study  examined  the  effects  of  SLCO1B1 genetic polymorphism on the fasting plasma 
concentrations of individual bile acids and a bile acid synthesis marker in 65 healthy subjects 
(Study II). In another retrospective study with 143 healthy individuals, the effects of CYP7A1 
genetic polymorphism and gender as well as SLCO1B1 polymorphism on the fasting plasma 
levels of individual bile acids and the bile acid synthesis marker were investigated (Study 
III). The effects of SLCO1B1 polymorphism on the pharmacokinetics of exogenously 
administered UDCA were evaluated in a prospective genotype panel study including 27 
healthy volunteers (Study IV).  
 
A  robust,  sensitive  and  simple  HPLC-MS/MS  method  was  developed  for  the  simultaneous  
determination of 16 individual bile acids in human plasma. The method validation parameters 
for  all  the  analytes  met  the  requirements  of  the  FDA  (Food  and  Drug  Administration)  
bioanalytical guidelines. This HPLC-MS/MS method was applied in Studies II-IV. In Study 
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II, the fasting plasma concentrations of several bile acids and the bile acid synthesis marker 
seemed to be affected by SLCO1B1 genetic polymorphism, but these findings were not 
replicated in Study III with a larger sample size. Moreover, SLCO1B1 polymorphism had no 
effect on the pharmacokinetic parameters of exogenously administered UDCA. Furthermore, 
no consistent association was observed between CYP7A1 genetic polymorphism and the 
fasting plasma concentrations of individual bile acids or the bile acid synthesis marker. In 
contrast, gender had a major effect on the fasting plasma concentrations of several bile acids 
and also total bile acids.           
    
In conclusion, gender, but not SLCO1B1 or CYP7A1 polymorphisms, has a major effect on 
the fasting plasma concentrations of individual bile acids. Moreover, the common genetic 
polymorphism of CYP7A1 is unlikely to influence the activity of CYP7A1 under  normal  
physiological conditions. OATP1B1 does not play an important role in the in vivo disposition 
of exogenously administered UDCA.        
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INTRODUCTION 
 
Bile acids play an essential role in lipid digestion and cholesterol metabolism. They are 
synthesized in the liver, and secreted into the bile. The bile flow carries bile acids to the small 
intestine, where they facilitate fat absorption (Nathanson and Boyer 1991). The majority of 
bile acids are reabsorbed in the ileum and enter the portal circulation, through which bile 
acids come into contact with hepatocytes. Hepatocytes extract bile acids efficiently, and 
secrete them again into the bile. The whole recycling process of bile acids is referred to as the 
enterohepatic circulation, which involves the coordinated activities of various transporters 
expressed on the basolateral and apical membranes of hepatocytes and enterocytes (Dawson 
et al. 2009). Among these bile acid transporters, organic anion transporting polypeptide 1B1 
(OATP1B1) is expressed on the basolateral membrane of human hepatocytes and is partly 
responsible for the hepatocellular uptake of bile acids from the portal vein. OATP1B1 is 
encoded by the solute carrier organic anion transporter family, member 1B1 (SLCO1B1) 
gene. A great deal of in vitro and in vivo data have demonstrated that two common genetic 
variants of the SLCO1B1 gene, c.521T>C and c.388A>G, are associated with altered 
transport activity of OATP1B1. In vitro, several bile acids have been identified to be 
substrates of OATP1B1 (Niemi et al. 2011). However, no studies have investigated the effects 
of SLCO1B1 genetic polymorphism on the in vivo disposition of endogenous bile acids. 
Moreover, ursodeoxycholic acid (UDCA) is not only an endogenous bile acid but also a 
therapeutic drug, which is used for gallstone dissolution and cholestatic disease (Beuers 
2006). During each cycle of enterohepatic circulation, approximately 5% of the bile acid pool 
is eliminated via faeces (Russell 2003). Faecal loss of bile acids is compensated by their de 
novo synthesis in the liver. Cholesterol 7?-hydroxylase (CYP7A1) initiates the classical 
pathway of bile acid synthesis from cholesterol, and is generally thought to be the rate-
limiting enzyme of bile acid biosynthesis (Pellicoro and Faber 2007). Some common genetic 
variants of the CYP7A1 gene have been associated with variability in blood lipid levels (Lu et 
al. 2010). Nonetheless, no study has investigated the effects of CYP7A1 polymorphism on the 
fasting plasma concentrations of individual bile acids.        
 
The purpose of this thesis research was to evaluate the effect of SLCO1B1 polymorphism on 
the fasting plasma concentrations of endogenous individual bile acids, a bile acid synthesis 
marker, and the pharmacokinetics of exogenously administered UDCA. To achieve this aim, 
a high performance liquid chromatography tandem mass spectrometry method for the 
determination of individual bile acids was first developed. Moreover, the effects of CYP7A1 
polymorphism and gender on the fasting plasma concentrations of endogenous individual bile 
acids and the bile acid synthesis marker were investigated.  
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REVIEW OF THE LITERATURE 
1. Bile acids 
 
One important function of mammalian hepatocytes is the conversion of cholesterol into bile 
acids, which subsequently cross the canalicular membrane of hepatocytes and are secreted 
into bile. Bile secretion is essential for intestinal digestion and absorption of lipids. Moreover, 
bile is also an important elimination route for xenobiotics and endogenous compounds such 
as bilirubin, and steroid hormones (Nathanson and Boyer 1991). Bile acids together with 
phospholipids and cholesterol are the major organic solutes of bile, and form mixed micelles 
in bile. The vectorial excretion of bile acids from blood into the bile is the driving force for 
hepatic bile formation. The total bile acid pool in an adult human is about 2–4 g, most of 
which is stored in the gallbladder under the fasting state (Dawson et al. 2009).  
 
In comparison to blood, concentrations of bile acids in bile are about 1,000 times higher. 
Therefore, active transport across hepatocytes is necessary to overcome a concentration 
gradient. After bile acids reach the lumen of the small intestine, most of them are reabsorbed 
and finally return to the liver through the portal venous circulation. This process is referred to 
as the enterohepatic circulation of bile acids. Each cycle of the enterohepatic circulation of 
bile acids can recycle about 95% of bile acids secreted into the intestine; only 5% of bile 
acids escape intestinal reabsorption and are eliminated through faeces (Russell 2003). 
Therefore, a distinctive characteristic of bile acids is that they are highly conserved after their 
synthesis in the body. The ileum is the main site for the intestinal reabsorption of bile acids, 
which is mediated by apical sodium-dependent bile acid transporter (ASBT) on the apical 
membrane of enterocytes. After transcellular transfer to the basolateral membrane, bile acids 
are effluxed into the portal blood by organic solute transporter alpha-beta (OST?-OST?). 
Besides hepatocytes and enterocytes, these transporters are also expressed in the renal, biliary 
and  colonic  epithelium  to  maintain  bile  acid  homeostasis.  Bile  acids  in  the  portal  vein  are  
efficiently transported across the basolateral membrane of hepatocytes by the sodium-
dependent taurocholate cotransporting polypeptide (NTCP) and sodium independently by 
organic anion transporting polypeptides (OATP). The recycled bile acids together with the 
newly synthesized portion are then secreted again into the biliary canaliculi by the bile salt 
export pump (BSEP) (Alrefai and Gill 2007) (Figure  1). In addition to enterohepatic 
circulation, another conservation mechanism of bile acids is cholehepatic shunting, in which 
bile acids in the bile duct lumen are reabsorbed via cholangiocytes and the periductular 
capillary plexus (Gurantz et al. 1991; Yeh et al. 1997).  
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Figure 1. Role  of  transporters  in  the  enterohepatic  circulation  of  bile  acids.  BA,  bile  acids;  
NTCP, sodium-dependent taurocholate cotransporting polypeptide; OATP, organic anion 
transporting polypeptide; MRP, multidrug resistance-associated protein; BSEP, bile salt 
export pump; ASBT, apical sodium-dependent bile acid transporter; OST???, organic solute 
transporter alpha-beta. The numbers connected to each transporter indicate the corresponding 
section of this thesis. Adapted from Alrefai and Gill (2007).  
 
In addition to their well-established roles in fat absorption and cholesterol homeostasis, 
extensive data emerging during the past two decades have indicated that bile acids are also 
important endocrine signalling molecules (Houten et al. 2006; Keitel et al. 2008; Thomas et 
al. 2008; Hylemon et al. 2009; Hageman et al. 2010). For example, bile acids can activate the 
mitogen-activated protein kinase (MAPK) pathway, and protein kinase A and C. They are 
ligands of the G-protein-coupled receptor (GPCR) TGR5. Bile acids are also natural ligands 
of nuclear receptors, such as farnesoid X receptor ? (FXR?), pregnane X receptor (PXR), 
constitutive androstane receptor, vitamin D receptor and liver X receptor (LXR) (Thomas et 
al. 2008; Hylemon et al. 2009). Among these nuclear receptors, FXR? mediates the 
enterohepatic circulation of bile acids, and the feedback regulation of bile acid synthesis. The 
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activation of FXR? by bile acids in the liver and intestine can prevent the accumulation of 
toxic bile acids (Chiang 2002; Russell 2003; Houten and Auwerx 2004). For example, FXR? 
activation results in increased conjugation of bile acids in the liver and elevated expression of 
basolateral bile acid transporters in the intestine. 
 
Moreover, bile acids may be involved in the development of certain human diseases, 
including cancer. In animal models, bile acids are implicated in different aspects of 
carcinogenesis. Epidemiological studies have also revealed correlations between serum or 
faecal concentrations of hydrophobic bile acids and the incidence or severity of cancer, 
mainly colorectal cancer (Debruyne et al. 2001; Bernstein et al. 2005; Zimber and Gespach 
2008). Hydrophilic bile acids, namely UDCA and its glycine and taurine conjugates, have 
been tested in the prevention and treatment of colorectal cancer in both experimental models 
and humans (Herszenyi et al. 2008).  
 
1.1 Biosynthesis of bile acids 
 
The de novo synthesis of bile acids starts from cholesterol (Figure 2). The adult human liver 
can transform about 500 mg of cholesterol into bile acids each day (Russell 2003). Bile acid 
synthesis is the major route of cholesterol metabolism in the body, and represents about 90% 
of cholesterol breakdown (Russell 2009). Chenodeoxycholic acid (CDCA) and cholic acid 
(CA) are classified as primary bile acids in humans, since they are the direct products of the 
synthetic pathways (Lefebvre et al. 2009). In principle, four steps of chemical modification 
are needed to make CA and CDCA from cholesterol, including (a) 7?-hydroxylation of the 
steroid nucleus, (b) modification of ring structures, (c) oxidation and shortening of the side-
chain, and (d) conjugation with glycine or taurine (Russell 2003). To date, at least 16 
enzymes have been found to participate in bile acid biosynthesis (Russell 2009). Two 
important pathways describe these reactions of bile acid synthesis: the classic (neutral) 
pathway and alternative (acidic) pathway (Russell 2003; Pellicoro and Faber 2007; Russell 
2009). The classic pathway occurs in the endoplasmic reticulum, where cholesterol initially 
undergoes 7?-hydroxylation with the catalysis of CYP7A1, a microsomal cytochrome P450 
(CYP) enzyme exclusively residing in the liver. CYP7A1 is considered the rate-limiting 
enzyme of this pathway. On the other hand, the mitochondria are the cellular sites for the 
alternative pathway, which is initiated with the hydroxylation of the C-27 side chain of 
cholesterol, being catalyzed by the sterol 27-hydroxylase (CYP27A1). The product of the 
first step, 5-cholesten-3?-27-diol, is then hydroxylated at the C-7 position by another CYP 
enzyme, oxysterol 7?-hydroxylase (CYP7B1). The following steps of this pathway then 
greatly overlap with those of the classic pathway. The 7?-hydroxy intermediates formed by 
CYP7A1 (classic) or CYP7B1 (acidic) continue to undergo ring modification to produce 3-
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oxo, ?4 intermediates by 3?-hydroxy- ?5 - C27-steroid oxidoreductase (HSD3B7). Structural 
modification by HSD3B7 includes the isomerization of the double bond from C5 to C4 and 
also the oxidation of the 3?-hydroxyl to 3-oxo group. Subsequently, depending on the 
involvement of microsomal sterol 12?-hydroxylase (CYP8B1), the HSD3B7 products pass in 
two directions: the formation of CA after 12?-hydroxylation by CYP8B1, and the production 
of  CDCA in  the  absence  of  CYP8B1 catalysis.  Thus,  CYP8B1 activity  determines  the  ratio  
between CA and CDCA.  
 
From here on, the site of reactions moves from the lipophilic endoplasmic reticulum to the 
hydrophilic cytosol, where the 12?-hydroxylated intermediates produced by CYP8A1 and 
those escaping CYP8A1 catalysis are subject to reduction of the C4 double bond by ?5 – 3-
oxosteroid 5?-reductase (AKR1D1), and subsequently reduction of the 3-oxo group to the 3?-
hydroxyl group by 3?-steroid dehydrogenase (AKR1C4). The following three steps of the 
biosynthetic cascade are catalyzed by mitochondrial CYP27A1, which also starts the acidic 
pathway. CYP27A1 first adds a hydroxyl group at C27, and then oxidizes it to an aldehyde 
and finally to a carboxylic acid group (Pikuleva et al. 1998). The final stage of primary bile 
acid production is performed in another organelle, the peroxisome. Bile acid coenzyme A 
ligase (BAL) starts the first step in the peroxisome by conjugating the sterol intermediates 
with coenzyme A. Next, the isomerization of C25 from R to S is achieved by 2-methylacyl-
coenzyme A racemase (AMACR). Further, the new 25(S) isomer is converted to a 24,25-
trans-unsaturated derivative with the assistance of branched-chain acyl-CoA oxidase 
(ACOX2), followed by hydration and oxidation at the ?24 bond by D-bifunctional protein 
(DBP). Finally, the peroxisomal thiolase 2 (SCP2) catalyzes the cleavage of the C24-C25 
bond to produce a C24 bile acid coenzyme A and propionyl-coenzyme A, which is conjugated 
with either taurine or glycine by bile acid coenzyme A:amino acid N-acyltransferase (BATT) 
before secretion into the bile canalicular lumen (Falany et  al. 1994). The majority of the 
circulating bile acids are glycine or taurine conjugates, which have pKa values  of  
approximately 2 and 4, respectively. Therefore, most bile acids exist in their anionic form at 
physiological pH, and are also called bile salts (Meier and Stieger 2002; Alrefai and Gill 
2007). In humans, 200 mg of CA and 100 mg of CDCA are synthesized on average per day 
(Hofmann and Hoffman 1974). Conjugated bile acids are secreted into the small intestine, 
where bacterial enzymes deconjugate bile acids by hydrolysis of the amide bond connecting 
bile acids with the amino group of glycine and taurine. Further in the large intestine, and 
possibly in the terminal ileum, bacterial enzymes continue to remove the 7?-hydroxyl group 
of bile acids to generate 7-deoxy bile acids, which are termed secondary bile acids. The 7-
dehydroxylation of CDCA and CA produces lithocholic acid (LCA) and deoxycholic acid 
(DCA), respectively. Several enzymes in anaerobic bacteria mediate the dehydroxylation at 
C-7, with the involvement of a 3-oxo4,5?6,7 resonating  intermediate (Ridlon et al. 2006). 
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UDCA is formed in the colon by bacteria-mediated 7?-epimerization of CDCA (Figure  2) 
(MacDonald et al. 1982).   
 
 
 
Figure 2. Bile acid synthesis. CYP7A1, cholesterol 7?-hydroxylase; CYP27A1, sterol 27-
hydroxylase; CYP7B1, oxysterol 7?-hydroxylase; HSD3B7, 3?-hydroxy- ?5 - C27-steroid 
oxidoreductase; CYP8B1, sterol 12?-hydroxylase; AKR1D1, ?5 – 3-oxosteroid 5?-reductase; 
AKR1C4, 3?-steroid dehydrogenase; BAL, bile acid coenzyme A ligase; AMACR , 2-
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methylacyl-coenzyme A racemase; ACOX2, branched-chain acyl-CoA oxidase; DBP, D-
bifunctional protein; SCP2, peroxisomal thiolase 2; BATT, bile acid coenzyme A:amino acid 
N-acyltransferase. (A)(B)(C)(D) indicate the four types of chemical modifications involved 
in  the  production  of  CA  and  CDCA  from  cholesterol,  namely,  (A)  7?-hydroxylation  of  the  
steroid nucleus, (B) modification of ring structures, (C) oxidation and shortening of the side-
chain, and (D) conjugation with glycine or taurine. Adapted from (Goodwin et al. 2003; 
Russell 2003; Pellicoro and Faber 2007). 
 
1.2 Regulation of bile acid synthesis 
 
Bile acid synthesis is precisely regulated in the liver (Russell 2003). The accumulation of bile 
acids decreases their synthesis via a negative feedback mechanism, which reduces the 
expression of CYP7A1 and CYP8B1 (Norlin and Wikvall 2007). Conversely, when 
cholesterol accumulates, bile acid synthesis is induced via a positive feedback mechanism, 
that works through the activation of CYP7A1. During feedback regulation, the suppression of 
CYP7A1 and CYP8B1 is triggered by the binding of bile acids to FXR. FXR subsequently 
activates the transcription of short heterodimeric partner (SHP), which continues to inhibit 
the  liver  receptor  homologue-1  (LRH-1).  LRH-1  is  essential  for  the  activation  of  genes  
encoding CYP7A1 and CYP8B1. Limiting cholesterol accumulation is regulated by LXR?, 
which is activated by the binding of oxysterols. Together with LRH-1, LXR? stimulates the 
transcription of the CYP7A1 gene (Russell 2009).  
 
1.3 Bile acid synthesis marker 
 
Due to the important role of bile acid synthesis in cholesterol metabolism and other 
physiological activities, a biomarker of bile acid synthesis rate is highly desired. The 
conversion of cholesterol into 7?-hydroxycholesterol by CYP7A1 is the rate-limiting step of 
the  classical  pathway,  which  accounts  for  more  than  75% of  bile  acid  synthesis  in  humans.  
Therefore, 7?-hydroxycholesterol was first proposed as a marker of the bile acid synthesis 
rate. However, it was later found that peroxidation of cholesterol could also produce 7?-
hydroxycholesterol during sample storage. Later, 7?-hydroxy-4-cholesten-3-one, an 
intermediate product following the 7?-hydroxylation of cholesterol, was investigated as a 
marker  of  the  bile  acid  synthesis  rate  in  humans  (Axelson et  al. 1988). 7?-Hydroxy-4-
cholesten-3-one  was  also  found  to  closely  reflect  the  activity  of  CYP7A1,  the  rate-limiting  
enzyme of bile acid synthesis (Axelson et al. 1991). In the past two decades, 7?-hydroxy-4-
cholesten-3-one  has  served  successfully  as  a  marker  of  the  bile  acid  synthesis  rate  in  a  
number of clinical and animal studies that have investigated the effects of disease, diet, and 
drug administration on bile acid synthesis. A good clinical example showing the diagnostic 
value of 7?-hydroxy-4-cholesten-3-one is cerebrotendinous xanthomatosis, which is a rare 
disease caused by a defective CYP27A1 gene. CYP27A1 has multiple functions in bile acid 
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synthesis. To compensate for the reduction of bile acid synthesis caused by the disruption of 
CYP27A1, CYP7A1 activity is enhanced, leading to an accumulation of 7?-hydroxy-4-
cholesten-3-one (Björkhem and Hansson 2010). Thus, the HPLC-MS/MS quantification of 
??-hydroxy-4-cholesten-3-one has been recently investigated as a diagnostic test for 
cerebrotendinous xanthomatosis (DeBarber et al. 2010).   
 
1.4 CYP7A1  
 
CYP7A1 catalyzes the 7?-hydroxylation of cholesterol, which is the first and a rate-limiting 
step in the classical pathway of bile acid synthesis. The crucial role of CYP7A1 in bile acids 
synthesis was demonstrated by inactivation of Cyp7a1 in mice (Ishibashi et al. 1996; 
Schwarz et al. 1996). In humans, a homozygous deletion mutation of the CYP7A1 gene is 
associated with high levels of low-density lipoprotein (LDL)-cholesterol and plasma 
triglycerides. Furthermore, these CYP7A1-deficient subjects are resistant to statin therapy 
(Pullinger et  al. 2002). The regulation of CYP7A1 expression mainly occurs at the 
transcriptional level. Bile acids inhibit CYP7A1 transcription via a negative feedback 
mechanism, mediated by the nuclear receptor FXR (Norlin and Wikvall 2007). Another 
regulator  is  cholesterol,  which  may  affect  CYP7A1  transcription  through  LXR?.  However,  
the regulatory role of cholesterol appears to be species-specific (Gilardi et al. 2007; Norlin 
and Wikvall 2007). From a pharmacological perspective, bile acid binding resins can be 
considered to target the negative feedback regulation of CYP7A1 to enhance the metabolism 
of plasma cholesterol. With more discoveries concerning the regulatory network of CYP7A1, 
new drugs have been designed to target this key enzyme in cholesterol metabolism (Gilardi et 
al. 2007).   
  
1.4.1 CYP7A1 pharmacogenetics 
 
Due to the important role of CYP7A1 in cholesterol homeostasis, it has been hypothesized 
that genetic variations in the CYP7A1 gene might contribute to inheritable variations in 
plasma lipid levels. An association was first identified between plasma LDL cholesterol 
levels and two SNPs in the promoter, g.-203A>C (rs3808607) and g.-469T>C (rs3824260), 
which were in nearly complete linkage disequilibrium (Wang et al. 1998). It was found that 
plasma LDL cholesterol concentrations were higher in g.-203C homozygotes (n = 57) than in 
g.-203A homozygotes (n = 105). This association was replicated in a larger-scale study with 
2330 subjects, which showed similar relationship in men but not women (Couture et al. 
1999). However, a contrary trend was observed in 139 Dutch hypertriglyceridaemic patients 
(Hofman et al. 2004). Furthermore, no association was seen in male Swedish populations 
(Abrahamsson et al. 2005) and in Dutch patients with coronary atherosclerosis (Hofman et al. 
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2005). In a very recent genome-wide association study screening about 2.6 million SNPs in 
more than 100,000 individuals of European ancestry, a CYP7A1 SNP, rs2081687, showed a 
genome-wide significant association with lipid traits, namely, total cholesterol and LDL 
cholesterol (Teslovich et al. 2010). 
 
In  addition  to  a  direct  association  with  plasma  lipid  levels,  CYP7A1 polymorphism also 
affects the response of plasma lipids or bile acid synthesis to different interventions, such as 
dietary change, drug therapy and surgery. A retrospective analysis of a Czech MONICA study 
revealed that g.-203A>C polymorphism strongly influenced the extent of the reduction of 
total plasma cholesterol after reduced dietary intake of fat for an 8-year period. Specifically, a 
significant decrease in total plasma cholesterol was observed in 23 subjects homozygous for 
the g.-203C allele, but not in 29 subjects homozygous for g.-203A allele (Hubacek et  al. 
2003). In another prospective study, individuals with the g.-203CC genotype were also more 
sensitive  to  a  high  fat  diet  challenge  than  those  with  the  g.-203AA  genotype  (Kovar et  al. 
2004). Similarly, a trial including 82 dyslipidemic male individuals showed that a fat-reduced 
diet resulted in a significantly greater reduction in plasma triglyceride concentrations in 
participants with one or two C alleles than those homozygous for the A allele (Barcelos et al. 
2009). Statin therapy is used along with dietary intervention to lower the plasma lipid levels. 
Quite a few studies have been conducted to investigate the influence of CYP7A1 
polymorphism on the response to statins. For example, g.-203C allele was significantly 
associated with a lower reduction of LDL-cholesterol levels in 324 hypercholesterolemic 
patients receiving 10 mg/day of atorvastatin for 52 weeks (Kajinami et al. 2004). 
Consistently, a poor response to pravastatin was also observed in g.-203C allele carriers in 
terms of serum total cholesterol lowering (Hofman et al. 2005). A surgerical example of the 
effects of CYP7A1 polymorphism is ileal resection, which may lead to malabsorption of bile 
acids, subsequently resulting in an upregulation of CYP7A1 activity. After ileal resection, g.-
203A homozygotes had a two-fold higher 7?-hydroxy-4-cholesten-3-one/cholesterol ratio (a 
marker of the bile acid synthesis rate) than g.-203CC homozygotes (Lenicek et al. 2008).  
 
Epidemiological  data  have  shown  that  disturbances  of  blood  lipids  are  associated  with  the  
occurrence of several diseases, such as atherosclerosis and cholesterol gallstone disease. 
Therefore, CYP7A1 might be a candidate gene related to the causes of these diseases. g.-
203A>C polymorphism was found to influence the progression of atherosclerosis in 715 male 
patients after two years of atorvastatin therapy. The progression of atherosclerosis in CC 
carriers was more rapid than in AA carriers (Hofman et al. 2005). A direct association 
between g.-203A>C polymorphism and subclinical atherosclerosis was observed in 84 
healthy postmenopausal women. Consistently, the g.-203C allele presented a higher risk, 
indicated by the presence of atherosclerosis and a higher carotid and femoral intima-media 
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thickness (Lambrinoudaki et al. 2008). A comparison of allele frequencies between 105 
gallbladder stone disease patients and 274 control subjects suggested that the g.-203A allele 
might be a risk factor for gallbladder stone disease in the Chinese population (Jiang et  al. 
2004), whereas this finding was not replicated in a North Indian population (Srivastava et al. 
2010) or a Mexican population (Sanchez-Cuen et  al. 2010).  By  contrast,  in  a  North  Indian  
population, the g.-203CC genotype was a risk factor of gallbladder cancer, particularly in 
women (Srivastava et  al. 2008; Srivastava et  al. 2010). Secondary bile acids, mainly DCA 
and LCA, have been implicated in colorectal carcinogenesis (Reddy et al. 1976). A case-
control study in Japanese individuals found that the g.-203CC genotype was associated with a 
decreased risk of proximal colon cancer, but not with distal or rectal colon cancer, with an 
odds ratio of 0.63 compared to the g.-203AA genotype (Hagiwara et al. 2005). A similar 
association was also observed between g.-203A>C and proximal colon adenoma, which is a 
well-recognized precursor lesion of colorectal cancer (Tabata et al. 2006). 
 
2. Role of transporters in the enterohepatic circulation of bile acids 
 
The lipid bilayer membrane of the cell presents a barrier to the movement of substances into 
and out of the cell. Lipophilic compounds can easily cross the cell membrane by passive 
diffusion down a concentration gradient. However, the membrane penetration of charged 
compounds (e.g. amino acids, glucose, bile acids) is limited. Thus, the translocation of such 
compounds across the cellular membranes necessitates specialized proteins known as 
transporters (Gruters 2007; Klaassen and Aleksunes 2010; Matsuo 2010). A number of 
knock-out rodent models as well as studies on transporter-deficient humans have indicated 
that transporters are critical for many physiological processes, such as the circulation of 
nutrients and removal of metabolic waste. Depending on the energy requirement, transporters 
can be divided into two types: facilitative transporters and active transporters. Facilitative 
transporters mediate solute movement down a concentration gradient or an electrical gradient 
without energy consumption, while energy-dependent active transporters can move solutes 
against a concentration gradient. Furthermore, according to the direction of movement of 
their substrates, transporters can be classified as influx (into cell) and efflux (out of cell) 
transporters. The influx transporters involved in drug transport mainly belong to two solute 
carrier superfamilies: solute carrier organic anion transporter (SLCO), and solute carrier 
(SLC) (Ciarimboli 2008; Srimaroeng et al. 2008). Most efflux transporters are members of 
the adenosine triphosphate (ATP)-binding cassette (ABC) superfamily, which utilizes ATP as 
an energy source (Choudhuri and Klaassen 2006; Kosters and Karpen 2008). 
 
Bile acid transporters occupy a prominent place in the enterohepatic circulation of bile acids 
and bile acid homeostasis. The past two decades have witnessed significant progress in 
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discovering bile acid transporters and identifying their function with the development of 
molecular cloning (Trauner and Boyer 2003; Kullak-Ublick et al. 2004). These bile acid 
transporters will be reviewed in this section, with a focus on their function, substrates, 
inhibitors and genetic polymorphism. Considering the scope of this thesis, the regulation of 
these transporter proteins will not be discussed here, but has been summarized in several 
reviews (Trauner and Boyer 2003; Alrefai and Gill 2007; Pellicoro and Faber 2007; Dawson 
et al. 2009).   
  
2.1 Hepatocellular transport of bile acids 
 
To  recycle  bile  acids,  hepatocytes  must  be  able  to  transfer  them  efficiently  from  the  portal  
blood to the bile. This vectorial trans-hepatocellular movement occurs against an unfavorable 
concentration gradient, and hence requires the assistance of various transport systems on the 
basolateral (sinusoidal) and apical (canalicular) membranes of polarized hepatocytes (Trauner 
and Boyer 2003; Alrefai and Gill 2007).  
 
Bile acids in portal blood firstly pass fenestrae of the sinusoidal endothelial cells, and reach 
the Disse space, where they come into direct contact with the transport proteins expressed on 
the basolateral membrane of hepatocytes. Once inside hepatocytes, bile acids are shuttled to 
the canalicular membrane, where the excretory pole of hepatocytes is located, consisting of 
the border of the bile canaliculus (Trauner and Boyer 2003). Canalicular secretion of bile 
acids is the rate-limiting step of bile secretion by hepatocytes, which is mainly mediated by 
BSEP.    
 
2.1.1 Basolateral uptake of bile acids 
 
Heaptocellular transport of bile acids is initiated by basolateral uptake, which is a highly 
efficient process. First-pass extraction rates of bile acids vary from 75 to 95%, depending on 
the chemical structure of bile acids, but irrespective of the systemic concentrations of bile 
acids (Kullak-Ublick et al. 2000). At the physiological pH of plasma, unconjugated bile acids 
mainly exist in an uncharged form. Thus, they can transverse the cell membrane by a passive 
diffusion mechanism. However, glycine and taurine conjugated bile acids, most of which 
exist in a charged form, require active transporters for their hepatocellular uptake. Basolateral 
uptake of bile acids occurs against a 5- to 10-fold concentration gradient between the portal 
blood and hepatocellular cytosol. This process is driven by both sodium-dependent and 
sodium-independent mechanisms (Meier 1995). 
      
2.1.1.1 Sodium-dependent bile acid transport 
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The sodium-dependent uptake of bile acids by the liver has been investigated using different 
experimental models, such as purified basolateral plasma membrane vesicles, isolated 
hepatocytes and perfused rat liver (Meier 1995). This type of pathway is characterized by a 
dependency on sodium, and a high affinity for conjugated bile acids. Most studies indicate 
that NTCP is the most important transporter governing the sodium-dependent pathway. In 
addition to NTCP, microsomal epoxide hydrolase (mEH) has also been suggested to 
participate in sodium-dependent transport (Alves et  al. 1993; von Dippe et al. 1993; von 
Dippe et al. 1996).        
 
2.1.1.1.1 NTCP 
 
NTCP  (human:  NTCP,  animal:  Ntcp)  is  a  membrane  glycoprotein  consisting  of  349  amino  
acids. Ntcp was initially cloned from rat liver (Hagenbuch et al. 1990), and later from human 
liver (NTCP) (Hagenbuch and Meier 1994). Human NTCP belongs to the SLC10 family of 
solute carrier proteins, and is encoded by the gene SLC10A1, which is mapped to 
chromosome 14q24.1-24.2 (Geyer et al. 2006). Both unconjugated and conjugated bile acids 
are physiological substrates of NTCP (Table 1) (Boyer et al. 1994; Hagenbuch and Meier 
1994; Platte et al. 1996; Kramer et al. 1999; Hata et al. 2003), whereas the former exhibit 
lower  affinities  than  the  latter.  The  predominant  role  of  Ntcp/NTCP in  sodium-coupled  bile  
acid uptake is supported by the following evidence. First, high-level expression of 
Ntcp/NTCP is strictly limited to the liver. Second, during rat development, Ntcp expression 
follows a similar ontogeny to sodium-dependent bile acid uptake (Boyer et al. 1993). Third, 
the  Km values of Ntcp-mediated taurocholate uptake are similar to those obtained from 
isolated rat hepatocytes. Lastly, antisense studies indicate that inhibition of Ntcp expression 
reduced by more than 90% the uptake of taurocholate in Xenopus laevis oocytes injected with 
rat liver mRNA (Hagenbuch et al. 1996). No NTCP knockout mice have been described to 
exemplify the predominant role of NTCP. Besides bile acids, some drugs and steroids are also 
NTCP substrates (Kim et al. 1999; Kramer et  al. 1999; Ho et  al. 2006; Mita et al. 2006; 
Leslie et al. 2007). For example, a study using isolated human hepatocytes indicated that 
NTCP may account for up to 35% of rosuvastatin uptake by hepatocytes (Ho et  al. 2006). 
Experiments using HeLa cells transfected with NTCP identified several potent NTCP 
inhibitors, including propranolol, cyclosporine and progesterone, while NTCP activity could 
also be enhanced by bupivicaine, lidocaine and quinidine (Kim et  al. 1999). A number of 
SNPs have already been identified in the SLC10A1 gene among different ethnic populations 
(Ho et al. 2004). In vitro experiments using human hepatocellular carcinoma cell (HepG2) 
cells also indicated that two of the NTCP genetic variants were associated with reduced 
transport activity (Ho et al. 2004). However, these functionally relevant SNPs are very rare, 
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and no in vivo study has shown the alteration of NTCP transport activity caused by these 
genetic variants.   
 
2.1.1.1.2 mEH 
 
mEH is a phase I metabolic enzyme, mainly responsible for the hydrolysis of reactive 
epoxide intermediates. Several studies have suggested that mEH also contributes to the 
sodium-dependent uptake of bile acids (Alves et al. 1993; von Dippe et al. 1993; von Dippe 
et al. 1996). mEH exists with distinct topological orientations, and type II is thought to target 
the plasma membrane (Zhu et al. 1999). However, data on the exact role of mEH in bile acid 
transport are still conflicting. mEH knockout mice are apparently normal in bile acid 
homeostasis (Miyata et  al. 1999). Conversely, sequencing of the mEH gene from a 
hypercholanemia patient identified a point mutation that was associated with an 85% 
reduction in the mEH protein level, while there was no change in NTCP expression (Zhu et 
al. 2003). Thus, further investigation is warranted to clarify the importance of mEH in the 
hepatocellular transport of bile acids.     
 
2.1.1.2 Sodium-independent bile acid transport 
 
In contrast to conjugated bile acids, the hepatic uptake of unconjugated bile acids in the portal 
blood mainly occurs in a sodium-independent manner (Trauner and Boyer 2003; Kullak-
Ublick et al. 2004). Bile acid uptake through this mechanism requires an exchange of 
intracellular  ions,  that  is,  usually  an  efflux  of  intracellular  HCO3- or  glutathione  (GSH)  
(Hagenbuch and Meier 2004). Unlike sodium-dependent uptake, sodium-independent uptake 
of bile acids involves several members of the OATP superfamily of transporters. OATPs have 
broad substrate specificities (Niemi 2007). In humans, two OATP members are known to 
transport bile acids: OAPT1B1, and OATP1B3. Among them, OATP1B1 is thought to be the 
most important for bile acid uptake (Kullak-Ublick et al. 2000; Meier and Stieger 2002).  
 
2.1.1.2.1 OATP1B1 
 
OATP1B1 was formerly known as OATP2, OATP-C and LST-1. It contains 691 amino acids 
and has a molecular mass of 84 kDa (Konig et  al. 2000a) (Figure 3). OATP1B1 is encoded 
by the SLCO1B1 gene, which is localized to chromosome 12q12 (Hagenbuch and Meier 
2004). The protein expression of OATP1B1 is strictly limited to the basolateral membrane of 
hepatocytes (Konig et al. 2000a), although small amounts of OATP1B1 mRNA have also 
been found in other tissues such as small intestinal enterocytes (Glaeser et al. 2007; Klaassen 
and Aleksunes 2010). Several transient and stable heterologous expression systems have been 
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utilized to indentify OATP1B1 substrates in vitro, such as Xenopus laevis oocytes and 
recombinant virus-infected cell lines (Niemi et al. 2011). OATP1B1 substrates include a 
broad range of compounds, which are often anionic amphipathic molecules with a molecular 
weight higher than 350. Another common characteristic of these OATP1B1 substrates is their 
high affinity-binding to albumin under normal physiological conditions (Hagenbuch and 
Meier 2004).  
 
More specifically, several bile acids, including CA, glycocholic acid (GCA), 
glycoursodeoxycholic acid (GUDCA), taurocholic acid (TCA) and tauroursodeoxycholic acid 
(TUDCA),  have  been  indentified  to  be  substrates  of  OATP1B1  (Table  1).  Moreover,  a  
fluorescent derivative of CDCA was transported by OATP1B1 with a Km of 1.45 µM, 
implying that CDCA might also be an OATP1B1 substrate (Yamaguchi et al. 2006). Besides 
bile acids, other known endogenous substrates of OATP1B1 include conjugated and 
unconjugated bilirubin, thyroid hormones, eicosanoids, cholecystokinin octapeptide, 
dehydroepiandrosterone sulphate, estradiol-17?-D-glucuronide, and estrone-3-sulphate 
(Niemi et al. 2011). Currently, approximately 60 exogenous compounds have been identified 
as OATP1B1 substrates (summarized in Niemi et  al. 2011). About half of them are drugs 
from several important therapeutic classes, such as cardiovascular drugs, anti-infective 
agents, anticancer drugs and HIV protease inhibitors (Niemi et al. 2011). For example, HMG-
CoA reductase inhibitors (statins), used to treat hypercholesterolemia, are all transported by 
OATP1B1 in vitro. Pravastatin was among the first indentified drug substrates of OATP1B1 
(Hsiang et al. 1999). The main function of OATP1B1 is to transfer its substrates from blood 
into the liver. Therefore, it may play an important role in drug elimination involving hepatic 
metabolism and biliary excretion.  
 
 
Figure 3. The transmembrane structure of OATP1B1. The structure was predicted by TMpred 
(Hofmann and Stoffel 1993) and rendered with TOPO2 (Johns).  
EXTRACELLULAR 
CYTOPLASM 
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2.1.1.2.2 OATP1B3 
 
OATP1B3 (formerly known as OATP8 and LST-2) shares about 80% identity with OATP1B1 
(Konig et al. 2000b). It is also a liver-specific transporter at the basolateral membrane of 
hepatocytes. Experiments in Xenopus laevis oocytes (XO) and human embryonic kidney 293 
cells (HEK293) demonstrated that OATP1B3 could transport TCA (Km = 42.2µM), GCA 
(Km = 43.4µM), CA (Km = 41.8µM), GUDCA (Km = 24.7µM) and TUDCA (Km = 15.9µM) 
(Briz et al. 2006; Maeda et al. 2006a). OATP1B3 has an overlapping substrate specificity 
with OATP1B1. Several endogenous substrates of OATP1B3 such as bilirubin, conjugated 
steroids, eicosanoids and thyroid hormones, are also transported by OATP1B1, except for the 
gastrointestinal peptide cholecystokinin, which is only transported by OATP1B3 (Ismair et al. 
2001). As for xenobiotics, digoxin, docetaxel, paclitaxel and amanitin appear to only be 
transported by OATP1B3 based on current data. OATP1B3 is encoded by the SLCO1B3 gene. 
    
The contribution of Oatp transporters to the hepatic uptake of bile acids has recently been 
investigated in Oatp1b2 (an orthologue of human OATP1B transporters) knockout mice. In 
one study, the plasma concentrations of several bile acids, including ?-muricholic acid, ?-
muricholic acid, CA, HDCA and UDCA, were 10- to 45-fold higher in Oatp1b2 knockout 
mice than in wild-type mice, suggesting  that the loss of Oatp1b2 function was not 
compensated by other transporters (Csanaky et al. 2011). However, this finding was not 
replicated by another study, which showed that the total plasma bile acid concentration was 
3-fold lower in Oatp1b2-knockout mice than in wild type mice (Schwabedissen et al. 2011). 
This discrepancy may be explained differences between the two studies in the ages of the 
mice (36–48 weeks vs. 10 weeks) (Schwabedissen et al. 2011). 
 
2.1.2 Basolateral efflux of bile acids 
 
Influx transporters predominantly control the direction of bile acid movement across the 
basolateral membrane of hepatocytes under normal physiological conditions. However, under 
cholestatic conditions, basolateral efflux transporters may be induced to help remove the 
toxic bile acids (Meier and Stieger 2002). Such efflux transport is mediated by multidrug 
resistance proteins (MRPs), specifically MRP3 and MRP4, which are localized to the 
basolateral membrane of hepatocytes (Soroka et al. 2001; Rius et al. 2003).    
 
2.1.3 Canalicular excretion of bile acids 
 
Canalicular excretion is the rate-limiting step in the vectorial movement of bile acids from the 
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hepatocyte into the bile duct. The concentrations of bile acids in the bile are more than 1000 
times higher than in the hepatocytes. This unfavorable concentration gradient indicates the 
presence of active transport across the canalicular membrane of hepatocytes. The primary 
canalicular bile acid transporter is BSEP. 
 
2.1.3.1 BSEP   
 
Due to its close relationship with P-glycoprotein (Multidrug resistance protein, MDR1), 
BSEP (BSEP: human, Bsep: animal) was first called the ‘‘sister of P-glycoprotein’’ (Childs et 
al. 1995). Later, BSEP was found to be able to efficiently transport conjugated bile acids, and 
was thus renamed as the bile salt export pump (Stieger et al. 2007). Although the exact 
substrate specificity of BSEP is species-dependent (Stieger and Geier 2011), BSEP/Bsep 
mainly transports monoanionic conjugated bile acids in an ATP-dependent manner (Klaassen 
and Aleksunes 2010). Besides bile acids, pravastatin is the only drug substrate of BSEP that 
has so far been identified (Hirano et  al. 2005). Additionally, a number of BSEP inhibitors 
have been reported, such as cyclosporine A, rifampicin and bosentan (Fattinger et  al. 2001; 
Byrne et al. 2002; Noe et  al. 2002). BSEP is encoded by the ABCB11 gene, which maps to 
chromosome 2q24 in humans (Byrne et al. 2002; Arrese and Ananthanarayanan 2004). BSEP 
is exclusively expressed on the canalicular membrane of hepatocytes. Evidence from both 
animals and humans has proven its predominant role in the excretion of bile acids into the 
bile (Gerloff et al. 1998). Knockout mice without BSEP expression suffer impaired bile 
secretion and consequently mild cholestasis (Wang et  al. 2001a). In humans, certain rare 
genetic mutations in the ABCB11 gene can result in progressive familial intrahepatic 
cholestasis (PFIC) type 2, a severe liver disease in which the biliary concentrations of bile 
acids are below 1% of the normal values (Strautnieks et al. 1998). This inheritable disease 
often leads to severe liver failure, for which the only cure is liver transplantation. More 
seriously, BSEP deficiency could recur in paediatric patients, even after liver transplantation 
(Jara et al. 2009). BSEP is also implicated in several forms of acquired liver diseases, such as 
drug-induced liver injuries, intrahepatic cholestasis of pregnancy (ICP), and viral hepatitis 
(Stieger and Geier 2011). For example, bosentan-induced liver injury could, at least partly, be 
attributed to the inhibition of BSEP, which results in the hepatic accumulation of cytotoxic 
bile acids (Fattinger et  al. 2001). Moreover, a common variant in the ABCB11 gene, 
c.1331C>T (Ala444Val), yielded a three-fold higher risk of developing drug-induced 
cholestasis in a study with 36 patients. c.1331C>T has also been recognized as a 
susceptibility factor of ICP by several studies (Pauli-Magnus et al. 2004; Meier et al. 2008; 
Dixon et al. 2009). These clinical findings are consistent with in vitro evidence. The c.1331C 
allele  was  associated  with  low BSEP protein  levels  in  a  study  of  110  healthy  liver  samples  
from Caucasians (Meier et al. 2006), and also in an in vitro expression system (Byrne et al. 
29 
 
2009). Moreover, a study including 21 human livers indicated that reduced mRNA levels of 
BSEP were associated with the c.1331C allele (Ho et al. 2010).   
 
2.1.3.2 MRP2 
 
MRP2,  well  known  as  the  bilirubin  conjugate  export  pump,  mediates  the  canalicular  
excretion of many divalent amphipathic conjugates with sulphate, glutathione and 
glucuronate. Divalent bile acids with two negative charges, such as sulphated tauro- or 
glycolithocholic acid (GLCA), are also substrates of MRP2. However, monovalent bile acids, 
BSEP substrates, are not transported by MRP2 (Trauner and Boyer 2003).  
 
2.2 Intestinal transport of bile acids 
 
About 95% of bile acids in the intestinal lumen traverse the enterocytes and go into the portal 
circulation. This process is a major component of bile acid enterohepatic circulation. 
Essentially, the trans-enterocellular movement consists of 3 steps: (1) the apical uptake of bile 
acids along the intestinal tract; (2) the intracellular shuttle of bile acids to the basolateral 
membrane  of  enterocytes;  and  (3)  the  efflux  of  bile  acids  from  the  enterocytes  via  an  ion  
exchange mechanism.  
 
2.2.1 Apical uptake of bile acids 
 
The apical uptake of bile acids involves both passive and active mechanisms. Passive 
absorption usually occurs in the proximal small intestine and the colon, whereas the terminal 
ileum reclaims bile acids by active uptake, which is mainly mediated by ASBT. The passive 
mechanism only accounts for a small part of bile acid recycling in the intestine. Therefore, 
ASBT plays a major role in the intestinal reabsorption of bile acids.  
 
2.2.1.1 ASBT  
 
As the second member of the SLC10 family of solute carrier proteins, ASBT (human: ASBT, 
animal: Asbt) is the ileal counterpart of hepatic NTCP. Asbt was first discovered by 
expression cloning from a hamster ileal cDNA library (Wong et al. 1994), and subsequently 
human ASBT was indentified in the ileum (Wong et al. 1995). In addition to ileal enterocytes, 
Asbt is also expressed in rat renal proximal tubule cells (Christie et al. 1996) and large rat 
cholangiocytes (Alpini et  al. 1997). Compared to NTCP, ASBT has narrower substrate 
specificity, strictly limited to bile acids (Craddock et al. 1998). Both unconjugated and 
conjugated bile acids can be efficiently transported by ASBT, whereas conjugated bile acids 
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exhibit higher affinities than the unconjugated forms (Craddock et al. 1998; Geyer et  al. 
2006). Moreover, ASBT affinities for dihydroxy bile acids are higher than those for 
trihydroxy bile acids among unconjugated bile acid species (Craddock et al. 1998). However, 
a reverse trend was observed for taurine-conjugated bile acids (Craddock et al. 1998). Similar 
to NTCP, ASBT activity is sodium-dependent with a stoichiometry of 2:1 sodium /bile acid 
(Weinman et al. 1998). The predominant role of ASBT in active intestinal uptake of bile acids 
is exemplified by loss-of-function mutations in the SLC10A2 gene (encoding human ASBT), 
which leads to primary bile acid malabsorption, an interruption of the enterohepatic 
circulation of bile acids and decreased plasma LDL cholesterol levels (Wong et  al. 1995; 
Oelkers et al. 1997). This is further strengthened by ASBT-knockout mice that are 
characterized by the malabsorption of bile acids and the absence of enterohepatic circulation 
of bile acids (Dawson et  al. 2003). Moreover, the concept of ASBT inhibition has been 
applied in drug development for the treatment of hypercholesterolemia, because a reduced 
circulating pool of bile acids promotes bile acid synthesis from cholesterol through feedback 
regulation (Bhat et al. 2003; Balakrishnan and Polli 2006).      
 
2.2.2 Basolateral efflux of bile acids 
 
After bile acids are taken up into the enterocyte, they are translocated to the basolateral 
membrane by bile acid-binding protein, and subsequently transported across the basolateral 
membrane by OST?-OST? transporters.  
    
2.2.2.1 OST?-OST? 
 
OST?-OST? was first cloned from the liver of skate Leucoraja erinacea (Wang et al. 2001b), 
followed by humans and mice (Seward et  al. 2003).  In  humans,  OST?-OST? is  mainly  
expressed in the small intestine, the kidney and the liver (Ballatori et al. 2005; Dawson et al. 
2005). OST? and OST? are the products of two different genes, but the function of OST?-
OST? requires the co-expression of the two subunits (Ballatori et al. 2005). The activity of 
OST?-OST? is  sodium-independent.  The  role  of  OST?-OST? in  basolateral  bile  acid  
transport is supported by the following evidence. The intestinal expression of OST?-OST? 
mRNA is similar to that of ASBT, with the highest levels in ileum. OST?-OST? is located on 
the lateral and basal membrane of ileal enterocytes, and efficiently transports major bile acid 
species (Ballatori et  al. 2005; Dawson et  al. 2005). Consistently, OST? null mice exhibit 
impaired intestinal bile acid absorption and altered bile acid metabolism, whereas no 
defective genetic mutations of OST?-OST? have been reported in humans. Besides bile 
acids, substrates of OST?-OST? include estrone-3-sulphate, digoxin, PGE2 and 
dehydroepiandrosterone sulphate (Wang et al. 2001b; Seward et al. 2003).  
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Table 1. Bile acids as substrates of transporters.  
Transporter Bile acid Km 
(µmol/l) 
Expression 
system 
References 
Hepatocyte-basolateral  
Influx transporter 
OATP1B1 CA 11.4 HEK293 (Cui et al. 2001) 
 GCA + XO (Kullak-Ublick et al. 2001) 
 GUDCA 5.17 HEK293 (Maeda et al. 2006a) 
 TCA 33.8 HEK293c18 (Hsiang et al. 1999) 
  13.6 XO (Abe et al. 1999) 
  + HEK293 (Konig et al. 2000a) 
  10.0 HEK293 (Cui et al. 2001) 
 TUDCA 7.47 HEK293 (Maeda et al. 2006a) 
 TLCA 3-sulphate + MDCKII (Sasaki et al. 2002) 
 CDCA-NBD 1.45 HepG2 (Yamaguchi et al. 2006) 
OATP1B3 CA 41.8 XO (Briz et al. 2006) 
 GCA 43.4 XO (Briz et al. 2006) 
 GUDCA 24.7 HEK293 (Maeda et al. 2006a) 
 TCA 42.2 XO (Briz et al. 2006) 
 TUDCA 15.9 HEK293 (Maeda et al. 2006a) 
 CDCA-NBD 0.54 HepG2 (Yamaguchi et al. 2006) 
NTCP GCA 27 CHO (Schroeder et al. 1998) 
 GUDCA 0.376 HEK293 (Maeda et al. 2006a) 
 TCA 6.3 XO (Hagenbuch and Meier 1994) 
  6 XO (Kullak-Ublick et al. 1997) 
  34 CHO (Schroeder et al. 1998) 
  7.9 HeLa (Kim et al. 1999) 
 TCDCA 5 CHO (Schroeder et al. 1998) 
 TUDCA 14 CHO (Schroeder et al. 1998) 
  3.49 HEK293 (Maeda et al. 2006a) 
mEH TCA 352 Hepatocyte SER 
vesicles 
(Alves et al. 1993) 
Efflux transporter 
MRP3 GCA 248 Membrane 
vesicles of 
HEK293 cells 
(Zeng et al. 2000) 
MRP4 CA 14.8 V79 (Rius et al. 2006) 
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 LCA 7.7 V79 (Rius et al. 2006) 
 GCA 25.8 V79 (Rius et al. 2006) 
 GCDCA 5.9 V79 (Rius et al. 2006) 
 GDCA 6.7 V79 (Rius et al. 2006) 
 GUDCA 12.5 V79 (Rius et al. 2006) 
 TUDCA 7.8 V79 (Rius et al. 2006) 
Hepatocyte-apical 
BSEP GCA 11.1 Sf9 cell vesicles  (Noe et al. 2002) 
 TC 4.25 High Five 
insect cell 
(Byrne et al. 2002) 
  7.9 Sf9 cell vesicles (Noe et al. 2002) 
 TCDCA 4.8 Sf9 cell vesicles (Noe et al. 2002) 
 TUDCA 11.9 Sf9 cell vesicles (Noe et al. 2002) 
MRP2 TUDCA 127 Sf9 cell vesicles (Gerk et al. 2007) 
Enterocyte-apical 
ASBT CA 33.3 COS  (Craddock et al. 1998)  
  37 CHO-K1 (Weinman et al. 1998) 
 GCDCA 5.7 COS-1 (Craddock et al. 1998) 
 GDCA 2.0 COS-1  (Craddock et al. 1998) 
 GUDCA 4.1 COS-1 (Craddock et al. 1998) 
 TCA 13.3 COS-1 (Craddock et al. 1998) 
  12 CHO-K1 (Weinman et al. 1998) 
Enterocyte-basal 
OST?-
OST? 
GCA + MDCK (Ballatori et al. 2005) 
 GCDCA + MDCK  
 GDCA + MDCK (Ballatori et al. 2005) 
 GUDCA + MDCK (Ballatori et al. 2005) 
 TCA + MDCK (Ballatori et al. 2005) 
 TCDCA + MDCK (Ballatori et al. 2005) 
 TDCA + MDCK (Ballatori et al. 2005) 
 TUDCA + MDCK (Ballatori et al. 2005) 
 
HEK293, human embryonic kidney 293 cells; XO, Xenopus laevis oocyte; MDCK, Madin-
Darby Canine Kidney cells; HepG2, human hepatocellular carcinoma cell; CDCA-NBD, 
chenodeoxychilyl-(N?-NBD)-lysine; NBD, 7-nitrobenz-2-oxa-1,3-diazole; CHO, China 
hamster ovary cells; SER, smooth endoplasmic reticulum; V79, Chinese hamster lung 
fibroblasts V79; +, substrate of the transporter, but Km not available.  
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3. Role of hepatic uptake transporters in pharmacokinetics 
 
In addition to their physiological functions, more evidence is emerging to support the 
important roles of transporters in pharmacokinetics (Ho and Kim 2005). Primarily, 
pharmacokinetics comprises absorption, distribution, metabolism and excretion. These 
processes dictate the circulating levels of drug molecules in different parts of the body, and 
consequently determine drug efficacy and response. The movement of drug molecules across 
the lipid bi-layers is involved in every stage of pharmacokinetics.  
 
The  liver  is  the  major  organ  of  drug  elimination,  either  through metabolism or  secretion  of  
drugs and/or metabolites into bile. The efficient uptake of many drugs by the liver is 
facilitated by influx transporters on the basolateral membrane of hepatocytes. Most hepatic 
uptake transporters belong to the solute carrier superfamily, including NTCP, OATPs, the 
organic anion transporters (OATs), and the organic cation transporters (OCTs). Four isoforms 
of them are considered to be important in hepatic drug uptake, namely OATP1B1, OATP1B3, 
OATP2B1, and OCT1 (Giacomini et al. 2010). As mentioned in sections 2.1.1.2.1 and 
2.1.1.2.2, OATPs transport a variety of amphiphilic organic compounds via a sodium-
independent mechanism. OCTs mediate the uptake of relatively hydrophilic and small cations 
across the plasma membrane, and the major representative in the liver tissue is OCT1 
(Giacomini et al. 2010). Many endogenous compounds and drugs interact with OCT1, such 
as acetylcholine, corticosterone, progesterone, metformin, quinidine, verapamil and acyclovir 
(Koepsell et al. 2007). OATs catalyze the transport of endogenous and exogenous anions, and 
they appear to be most important in the renal excretion of drugs (Giacomini et al. 2010). 
OAT2 is the major isoform found in the liver. Its substrates include prostaglandin, 
peobenecid, and diclofenac (Miyazaki et al. 2004).  
 
Genetic factors or co-administered drugs may exert significant effects on the pharmacokinetic 
behaviour of these drugs, the hepatic uptake of which is facilitated by these transporters. 
More details on the genetic factors influencing OATP1B1 activity will be presented in section 
4. The role of transporter-mediated hepatic uptake in the overall hepatic intrinsic clearance 
can be illustrated by the following equation:  
   CLint, all = PSu,influx ×  ??int??int???u,efflux                                                                                              (1) 
where PSu, influx and  PSu,efflux represent the basolateral membrane permeability of unbound 
drugs via the influx and efflux processes, respectively. CLint, all is the overall hepatic intrinsic 
clearance, while CLint is the intrinsic clearance incorporating both metabolism and biliary 
excretion (Shitara et al. 2006; Soars et al. 2009). When PSu, efflux is much lower than CLint, 
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Equation 1 can be approximated by the following equation: 
 CLint,all = PSu,influx                                                                                                               (2) 
In this case, the overall hepatic intrinsic clearance is predominantly determined by the hepatic 
uptake process and is thus uptake-limited.  
On the contrary, when PSu, efflux >> CLint, Equation 1 can be approximated by the following 
equation: CLint, all = PSu,in?lux ×  ??int??u,ef?lux                                                                                             (3) 
In this case, all the processes can influence the overall hepatic intrinsic clearance. In 
particular, when PSu, influx = PSu, efflux, which occurs for lipophilic drugs with rapid membrane 
permeability, the overall hepatic intrinsic clearance (CLint, all) equals the intrinsic clearance 
(CLint). Therefore, the clearance of drugs with high permeability is unlikely to be affected by 
hepatic uptake transporters.  
 
4. Pharmacogenetics of SLCO1B1 
 
A large number of genetic variants have been identified among different populations in the 
SLCO1B1 gene, which encodes the OATP1B1 protein. About 42 of the variants are single 
nucleotide polymorphisms (SNPs) associated with amino acid changes (Niemi et  al. 2011). 
So far, two common nonsynonymous SNPs have been extensively studied both in vitro and in 
humans: c.521T>C (rs4149056) and c.388A>G (rs2306283). The c.521T>C SNP leads to an 
amino acid change from alanine to valine at position 174, and c.388A>G results in a 
replacement of asparagine with aspartic acid at amino acid position 130. These two SNPs are 
in partial linkage disequilibrium (LD) and form four haplotypes: *1A (c.388A-c.521T), and 
*1B (c.388G-c.521T), *5 (c.388A-c.521C) and *15 (c.388G-c.521C). The distribution of 
SLCO1B1 haplotypes differs greatly between ethnic populations. The combined frequency of 
the *5 and *15 haplotypes is about 15–20% in Europeans and 10–15% in Asians, but only 2% 
in Sub-Saharan Africans. Conversely, the *1B haplotype has  a  high  frequency  of  
approximately 77% in Sub-Saharan Africans compared to East Asians (63%), South/Central 
Asians (39%) and Europeans (26%) (Pasanen et al. 2008a).  
 
Various cell lines have been utilized to express wild-type OATP1B1 and mutants, such as 
human  embryonic  kidney  cells  (HEK293),  human  cervical  carcinoma  cells  (HeLa),  Madin-
Darby canine kidney cell strain II (MDCKII), and Xenopus laevis oocytes (Giacomini et al. 
2010; Niemi et al. 2011). In these in vitro models, SLCO1B1*5 and *15 haplotypes have been 
associated with a reduced uptake of both physiological and drug substrates by OATP1B1 
compared with the *1A reference haplotype. However, there are no consistent in vitro data on 
the relationship between the *1B haplotype and transporter function. Either increased 
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transport activities (bromosulfophthalein and estrone-3-sulphate) (Michalski et  al. 2002; 
Kameyama et al. 2005) or reduced activitites (cholyltaurine and rifampicin) (Michalski et al. 
2002; Tirona et al. 2003) have been associated with the *1B haplotype in vitro, whereas no 
change has been seen for many substrates (Kalliokoski et al. 2010).         
 
In agreement with cellular findings, clinical studies also indicate that SLCO1B1*5 and *15 
haplotypes predict impaired transport activity of OATP1B1 for a number of substrates, as 
reflected by higher exposure levels of these substrates in the blood circulation in comparison 
to the reference *1A haplotype. So far, the pharmacokinetics of more than 20 drugs has been 
found to be affected by the SLCO1B1 polymorphism (Niemi et al. 2011). Pravastatin was the 
first drug investigated. Statin drugs work through the inhibition of 3-hydroxy-3-
methylglutaryl coenzyme A reductase, which is expressed in hepatocytes. Therefore, factors 
determining statin concentrations in the liver may affect their efficacy. After oral 
administration of 40 mg pravastatin, subjects with at least one c.521C allele had 42–106% 
higher AUC values than those without this variant, as shown in different studies (Nishizato et 
al. 2003; Mwinyi et al. 2004; Niemi et al. 2004; Igel et al. 2006; Maeda et al. 2006b; Niemi 
et al. 2006a; Ho et al. 2007; Deng et al. 2008). Similar associations have been observed for 
atorvastatin, pitavastatin, rosuvastatin and simvastatin acid, but not fluvastatin or simvastatin 
lactone (Chung et al. 2005; Pasanen et al. 2006a; Niemi et al. 2006a; Ieiri et al. 2007; 
Pasanen et al. 2007; Deng et al. 2008). The largest effect of SLCO1B1 polymorphism on 
statin pharmacokinetics was observed for simvastatin acid, with a 3.2-fold increase in the 
mean AUC in c.521CC homozygotes compared to c.521TT homozygotes (Pasanen et  al. 
2006a). In one study, the SLCO1B1 genotype  did  not  influence  the  effects  of  single  statin  
doses on markers of cholesterol absorption and synthesis in healthy volunteers (Pasanen et al. 
2008b). The c.521T>C SNP appears to exhibit a gene-dose effect. For example, after 
ingestion of 20 mg atorvastatin, the AUC0-48 of atorvastatin in subjects with the c.521CC 
genotype was 144% higher than in those with the c.521TT genotype, and 61% higher than in 
those with the c.521TC genotype (Pasanen et  al. 2007). Thus, it may be concluded that a 
single copy of the c.521C allele is enough to cause a significant decrease in the transport 
capacity of OATP1B1, and that the effect is markedly enhanced by one more c.521C allele. 
    
In addition to potentially reducing the cholesterol-lowering efficacy of statin therapy, reduced 
hepatic uptake of statins may also increase the risk of myopathy, which is related to systemic 
exposure to statins. The effect of SLCO1B1 polymorphism on the incidence of statin-induced 
myopathy has been exemplified by a genome-wide association study in 85 patients with 
simvastatin-induced myopathy and 90 control patients without myopathy. In these 
participants, more than 300 000 SNPs were determined, and only a non-coding SNP in the 
SLCO1B1 gene was found to be strongly associated with myopathy. This variant is in almost 
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complete linkage disequilibrium with the c.521T>C SNP. Individuals homozygous for the 
c.521C allele have a 16.9-fold higher risk of myopathy than those homozygous for c.521T. 
This is consistent with a previous finding that the c.521C allele is associated with 
considerably higher systemic exposure to simvastatin acid, the active form of simvastatin 
(Pasanen et al. 2006a).      
 
In contrast to c.521T>C, the *1B haloptype (c.388A-c.521T) seems to be associated with 
enhanced transport activity of OATP1B1 in vivo in humans, being supported by the findings 
that plasma AUC of the OATP1B1 substrates pravastatin and repaglinide were about 30–35% 
lower in individuals with the SLCO1B1*1B/*1B genotype than in those with the 
SLCO1B1*1A/*1A genotype (Maeda et al. 2006b; Kalliokoski et al. 2008a). However, there 
was no similar effect of the *1B haloptype on the pharmacokinetics of rosuvastatin (Lee et al. 
2005; Choi et  al. 2008). Taken together with in vitro evidence, it can be suggested that the 
effect of the *1B haplotype is substrate specific.    
 
With respect to endogenous substrates, plasma or serum levels of bilirubin have been 
reported to be related to SLCO1B1 genetic variations, whereas such relationships could be 
population specific. In a study performed in 23 healthy Japanese subjects, the serum 
unconjugated bilirubin concentration in carriers of the SLCO1B1*15 haplotype was 
significantly higher than in noncarriers. This was supported by another study comprising 42 
healthy Chinese volunteers (Zhang et al. 2007). Moreover, the SLCO1B1 c.521C/c.388G 
alleles predisposed to hyperbilirubinemia in Chinese patients (Huang et al. 2004; Huang et al. 
2005). However, in a study with 107 healthy European-American or African-Americans, 
there was no association between SLCO1B1 polymorphism and baseline plasma levels of 
either total or unconjuagted bilirubin (Ho et al. 2007). Additionally, a marker of the 
cholesterol synthesis rate, the fasting plasma desmosterol-to-cholesterol ratio, was 40% 
higher in individuals with the c.521CC than in those with the *1A/*1A genotype (Pasanen et 
al. 2008b). The underlying mechanism may be that genetically impaired hepatic uptake of 
bile acids by OATP1B1 leads to an elevated conversion of cholesterol into bile acids.  
 
5. UDCA 
 
5.1 UDCA 
 
UDCA (Figure 4) was first identified from bile extract of black bears. Bear bile extract has 
been a popular traditional Chinese medicine for thousands of years in Asian countries (Hagey 
et al. 1993; Feng et al. 2009). The modern use of UDCA as a cholesterol gallstone-dissolving 
agent was initiated by Japanese researchers (Makino et al. 1975). Nowadays, its clinical 
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application as a gallstone dissolution drug is much less important than its role in the treatment 
of chronic cholestatic diseases, particularly primary biliary cirrhosis (Abbas and Lindor 
2010). Some potential clinical applications of UDCA are also under investigation, such as the 
prevention of colorectal cancer (Herszenyi et al. 2008). The mechanisms of action of UDCA 
in curing cholestatic disease have not been completely elucidated. Proposed mechanisms 
include the stimulation of hepatobiliary secretion, inhibition of apoptosis and cytoprotection 
against hydrophobic bile acids (Pusl and Beuers 2006). Cholestatic liver disease is 
characterized by impaired hepatobiliary secretion, leading to the accumulation of toxic bile 
acids in hepatocytes. Different experimental models have shown that UDCA can stimulate 
hepatobiliary secretion to eliminate toxic compounds from the hepaotcytes (Beuers 2006). 
Toxic bile acids also induce apoptosis, which is an important mechanism of cell death in 
cholestatic liver disease. Both in vitro and in vivo studies have demonstrated that UDCA 
could block apoptosis through interrupting its classic pathways (Amaral et  al. 2009). 
Additionally, hydrophobic bile acids in bile are at millimolar levels, high enough to exert 
cytotoxicity extracellularly via the cell membranes of hepatocytes and cholangiocytes. UDCA 
conjugates are able to counteract the cytotoxic effects of hydrophobic acids by modulating 
the structure and composition of phospholipid-rich micelles in bile. Moreover, an increasing 
percentage of UDCA in bile makes bile more hydrophilic, and consequently less cytotoxic.  
 
Figure 4. Chemical structures of ursodeoxycholic acid, glycoursodeoxycholic acid and 
tauroursodeoxycholic acid 
 
5.2 Pharmacokinetics and metabolism of UDCA 
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UDCA is  administered  orally  in  its  acidic  form,  which  has  a  pKa of  5.1.  It  is  poorly  water  
soluble at pH < 7, and the solubility of its protonated form is 9 µmol/l (Hofmann 1994). After 
ingestion, UDCA is solubilized in mixed micelles of endogenous bile acids and 
phospholipids, and subsequently absorbed via passive nonionic diffusion primarily in the 
proximal small intestine, and to a small degree in the colon (Crosignani et al. 1996). The 
intestinal absorption of UDCA may be enhanced by a meal or decreased by the presence of 
cholestasis (Sauer et al. 1999). UDCA in the portal blood is efficiently taken up by 
hepatocytes with a first-pass extraction ratio ranging from 50 to 70% (Bachrach and 
Hofmann 1982). Both NTCP and OATPs mediate the hepatocellular uptake of UDCA (Maeda 
et al. 2006a). In the liver, UDCA is efficiently conjugated with glycine and taurine by BATT, 
and subsequently secreted into the bile duct by BSEP.  After UDCA and its conjugates reach 
the small intestine, most UDCA conjugates are reabsorbed via ASBT from the distal ileum. 
Therefore, like endogenous bile acids, therapeutic UDCA and its conjugates (Figure 4) also 
undergo enterohepatic circulation (Crosignani et  al. 1996). Non-absorbed UDCA and its 
conjugates enter the colon, where they undergo bacteria-mediated deconjugation and 
transformation into LCA. LCA is insoluble in the colonic content, and is mainly excreted via 
the faeces. After long-term administration, UDCA becomes the predominant bile acid species 
in the bile, ultimately accounting for 40–60% of the total bile acid pool (Hofmann 1994; 
Rubin et al. 1994).  
 
6. High performance liquid chromatography-tandem mass spectrometry for the 
determination of bile acid concentrations in human plasma 
 
6.1 Mass spectrometry fundamentals  
 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-charge ratio 
(m/z)  of  gas  phase  ions,  and  thus  can  be  used  to  determine  the  molecular  weight  of  
distinctively different molecules, ranging from inorganic salts to proteins (Ramanathan 
2009). MS plays an important role in elucidating chemical structures of molecules. The 
astonishing development of MS in recent decades has made it the most widely used 
bioanalytical tool and the gold standard for many pharmaceutical analyses (Chen et al. 2007; 
Tolonen et al. 2009). A very important application of the MS technique is quantitative HPLC-
MS/MS, which has grown to replace liquid chromatography-ultraviolet (LC-UV) and gas 
chromatography-mass spectrometry (GC-MS). The practical application of the MS technique 
is performed with a mass spectrometer, which is a device measuring mass-to-charge ratio of 
gas phase ions and their corresponding abundance. A mass spectrometer is composed of a 
sample  inlet,  a  mass  analyzer  and  a  detector  (Figure  5). The sample inlet of mass 
spectrometer could be a syringe, or a chromatographic system such as liquid chromatography 
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(LC) and gas chromatography (GC). The sample introduced by the sample inlet must be 
converted from the liquid or solid phase to the gas phase, and must be ionized before entering 
the mass analyzer. This process is achieved by the ion source. Currently, several types of ion 
sources have been commercialized. Among them, electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI) are the principal types of ion source used in 
quantitative bioanalysis. 
 
In ESI, the effluent from liquid chromatography first passes a fine capillary on which a high 
electric field is applied. Ions are formed in the solution via acid-base or redox chemistry. 
Droplets exiting the capillary tubing are sheared by high flow rates of nebulizer gas, and 
converted to the gas phase through some combination of ion evaporation and ion ejection 
mechanisms. ESI is usually considered as a soft ionization technique, because little 
fragmentation of ions occurs (Kebarle 2000). A great advantage of ESI is its ability to create 
multiple charges on a single molecule, which makes it suitable for the analysis of large 
molecules such as peptides and proteins. As for APCI, the effluent is evaporated by passing a 
tube with a relatively high temperature (above 400 ºC). Once exiting the heated region, the 
gaseous effluent together with nebulizer gas is subjected to a high-voltage corona discharge, 
leading to the formation of reagent ions. Ultimately, gas-phase protons transfer between 
reagent ions and analyte molecules results in the ionization of analytes (Duffin et al. 1992). 
APCI occurs in the gas phase and ESI in the liquid phase. Thus, it is possible for LC coupled 
with  APCI  to  utilize  a  nonpolar  solvent  as  the  mobile  phase.  Compared  to  ESI,  APCI  
generates more fragment ions relative to the parent ion, and is more suitable for compounds 
that are less polar and have a lower mass.  
 
The key component of a mass spectrometer is the mass analyzer, which is often the basis of 
differentiating various types of mass spectrometers. In this thesis, a triple quadrupole mass 
spectrometer was employed to perform the bioanalysis of bile acids. The quadrupole mass 
filter or the transmission quadrupole is a type of mass analyzer that utilizes the four parallel 
conducting rods arrayed such that a combination of voltages exists that permits the passage or 
filtering of a single m/z value. By varying the amplitude of the fields, a sequence of m/z ions 
is allowed to pass the mass analyzer to produce a mass spectrum. Low operating voltages and 
fast scanning capabilities make quadupole analyzers ideal for coupling with an LC system. In 
order to obtain more structural information, multiple mass analyses are often needed. 
Multiple analyses can be accomplished with individual mass spectrometer elements separated 
in space or using a single MS with a number of MS steps separated in time. For example, the 
triple quadrupole mass spectrometer, when operated in the multiple reaction monitoring 
(MRM) mode, offers a unique combination of sensitivity, specificity and dynamic range. 
Under MRM mode, the first mass analysis selects a specific m/z to  be  fragmented  in  the  
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collision cell, and the second mass analysis detects a specific product ion.  
 
Figure 5. Components of a mass spectrometer.  
 
6.2 Analysis of bile acids in human plasma  
 
In clinical practice, plasma bile acids are often measured when monitoring liver diseases 
(Goldberg and Brown 1987). Enzymatic assays are usually used in clinical laboratories due to 
their simplicity. The enzyme used for bile acid analysis is nicotinamide adenine dinucleotide 
(NAD+)-dependent 3?-hydroxysteroid dehydrogenase, which can oxidize the 3?-hydroxyl 
group of all bile acids to a 3-keto group coupled with the formation of a co-enzyme, NADH. 
NADH is measurable by ultraviolet (UV) or fluorometric methods. Furthermore, to improve 
assay sensitivity, this reaction can be followed by one more reaction using NADH to generate 
a reduced substrate that has higher fluorometric sensitivity (Qureshi et al. 1984). The 
enzymatic method is highly dependent on enzyme purity, and can only determine total bile 
acids (TBA). With growing interest in the physiological and pathological roles of bile acids, 
new methods for the analysis of bile acids in body fluids and tissues are needed. A large step 
towards  such  an  aim  was  the  introduction  of  chromatographic  separation  coupled  with  MS  
detection. Isomeric bile acids cannot be distinguished by MS alone (Figure  6). Therefore, 
chromatographic separation is often required prior to MS scanning. Before LC-MS, GC-MS 
was the most widely used method for the determination of bile acids in body fluids (Courillon 
et al. 1997; Roda et  al. 1998). However, the use of GC-MS is limited by tedious sample 
preparation work, which is particularly troublesome for routine application. Its high 
sensitivity coupled with relatively simple sample preparation have made HPLC-MS/MS an 
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ideal choice for the analysis of bile acids in various body fluids. Currently, most HPLC-
MS/MS methods for bile acid analysis employ a combination of reversed phase 
chromatography and ESI. HPLC-MS/MS has been used for bile acid analysis of various 
biological samples obtained from humans and rodents, such as plasma/serum, bile, liver, 
brain, faeces and cecal content (Griffiths and Sjovall 2009). When multiple reaction 
monitoring (MRM) (also referred to as selected reaction monitoring, SRM) mode is selected 
for the analysis of bile acids, the fragmentation of molecules occurs in a collision cell that is 
between two MS analyzers. Under the negative mode, taurine conjugated bile acids give a 
characteristic fragment ion at m/z 80 (SO3-),  while glycine conjugates give an ion at  m/z 74 
(H2NCH2CO2-). However, under the same ionization conditions, unconjugated bile acids do 
not produce a characteristic fragment with high intensity.  
 
The matrix effect refers to signal suppression or the enhancement of target analytes caused by 
coeluting compounds via alteration of the formation efficiency of analyte droplets and the 
amount of analyte ions in the gas phase (Annesley 2003). The strength of the HPLC-MS/MS 
method is weakened by the matrix effect, which may lead to inaccurate quantification and 
reduced sensitivity of analytes. Therefore, investigation of the matrix effect is an important 
issue in the validation of HPLC-MS/MS methods (FDA, 2001). Generally, APCI is less 
susceptible to matrix effects than ESI (Gosetti et  al. 2010). The strategies to overcome the 
matrix effect include modification of the sample extraction method and optimization of 
chromatographic separation (Taylor 2005). In addition, isotopically-labelled internal 
standards are used to correct for the matrix effect (Gosetti et al. 2010). The matrix effect of 
human serum on unconjugated, glycine- and taurine-conjugated bile acids has previously 
been investigated, and no significant ion suppression was observed (Burkard et al. 2005).  
 
Bile acid levels in plasma samples are quite low, particularly compared to the interfering 
molecules in the same sample matrix. Thus, extraction with a solvent or sorbent is required 
prior to introduction into HPLC-MS/MS, aiming to remove proteins, inorganic salts and 
lipids.  Bile  acids  can  usually  be  simply  extracted  from  plasma  with  a  direct  protein  
precipitation method using ethanol, methanol or acetonitrile. Another alternative is solid 
phase extraction (SPE). Compared to solvent extraction, an important advantage of SPE is its 
ability to remove inorganic ions. This greatly reduces the possibility of matrix effects on bile 
acid ions. The utilization of isotope-labeled bile acids as the internal standard is the best 
choice when available. Deuterium or C13-labelled bile acids are commercially available from 
several companies, such as Steraloids (www.steraloids.com) and Toronto Research Chemicals 
(www.trc-canada.com).  Recently, some new technologies have been introduced in the 
HPLC-MS/MS analysis of bile acids, such as an on-line method combining restricted access 
material (RAM) and the linear ion trap Fourier transform mass spectrometer (LTQ-FTMS) 
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(Bentayeb et al. 2008; Bobeldijk et al. 2008). 
 
 
Bile acid R R1 R2 
UDCA -H -OH -H 
CA -OH -H -OH 
CDCA -OH -H -H 
DCA -H -H -OH 
LCA -H -H -H 
R3, -OH, unconjugated; -NHCH2COOH, glycine 
conjugates; -H(CH2)2SO3H, taurine conjugates  
 
Figure 6. Structures of unconjugated, glycine- and taurine-conjugated bile acids.  
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AIMS OF THE STUDY 
 
The aim of this study was to investigate the effects of gender, and SLCO1B1 and CYP7A1 
genetic polymorphisms on the fasting plasma concentrations of bile acids, and also the role of 
SLCO1B1 polymorphism on the pharmacokinetics of exogenously administered UDCA. To 
this end, the specific aims of this study were as follows: 
 
1. To  develop,  optimize  and  validate  a  HPLC-MS/MS  method  for  the  determination  of  the  
plasma concentrations of 16 endogenous bile acids (Study I) 
2. To investigate the effects of gender, and SLCO1B1 and CYP7A1 genetic polymorphisms 
on the fasting plasma concentrations of bile acids, and a bile acid synthesis marker in 
healthy individuals (Studies II & III) 
3. To investigate the effects of genetic polymorphism in SLCO1B1 on the pharmacokinetics 
of exogenously administered UDCA in healthy individuals (Study IV) 
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MATERIALS AND METHODS 
 
1. Subjects 
 
All the subjects for Studies II and IV were recruited from a pool of more than 800 healthy 
volunteers genotyped for SLCO1B1 SNPs. Study III included volunteers enrolled in our 
previous pharmacokinetic studies (Backman et al. 2009; Karonen et al. 2010a; Tapaninen et 
al. 2010a; Karonen et al. 2010b; Tapaninen et al. 2010b; Tapaninen et al. 2010c; Tapaninen et 
al. 2010d; Honkalammi et al. 2011). The participants were ascertained to be healthy by 
medical history, clinical examination, and routine laboratory tests before entering the studies. 
None used any continuous medication. Only one subject (Study II) was a tobacco smoker. 
The use of all drugs, including oral contraceptive steroids, was prohibited for 1 week, use of 
grapefruit products for 3 days, and alcohol drinking for 1 day before blood sampling (Study II 
and III), or placebo or UDCA administration (Study IV). The overnight fast was 8 hours 
(starting at 00:00 h), and it was not controlled under in-house conditions. The last meal in the 
evening before blood sampling was a non-standardized normal-diet meal.     
 
2. Study design 
 
For Studies II and III, the blood samples were collected when the subjects participated in our 
previous pharmacokinetic studies (Pasanen et al. 2006a; Niemi et al. 2006b; Pasanen et  al. 
2007; Kalliokoski et al. 2008a; Kalliokoski et al. 2008b; Kalliokoski et al. 2008c; 
Kalliokoski et al. 2008d; Backman et al. 2009; Karonen et al. 2010a; Tapaninen et al. 2010a; 
Karonen et al. 2010b; Tapaninen et al. 2010b; Tapaninen et al. 2010c; Tapaninen et al. 
2010d; Honkalammi et al. 2011). Specifically, following an overnight fast, a 5-ml venous 
blood sample was drawn into a lithium heparin-containing tube from each individual, prior to 
drug administration between 7:30 and 8:30 in the morning. Plasma was separated within 30 
minutes and stored at -70 oC until analysis. Because these former pharmacokinetic studies 
consisted of one to five phases each and some individuals participated in more than one trial, 
the number of samples from each individual subject varied from one to ten (median 5) for 
study II, and one to four (median 1) for study III.  
  
Study IV was a fixed-order crossover study with two phases, and the washout period between 
the phases was at least one week. Following an overnight fast, the participants ingested 
placebo  or  a  single  150-mg dose  of  UDCA (Adursal® tablets, Leiras, Finland) with 150 ml 
water. They received a standardized warm meal 4 h after drug or placebo administration, and 
also  a  standardized  snack  after  7  h  and  10  h.  Blood  samples  (5  or  10  ml  each  time)  were  
drawn from a cannulated forearm vein into tubes containing ethylenediaminetetraacetic acid 
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(EDTA) immediately before and 0.5, 1, 2, 3, 4, 5, 7, 9, 12 and 24 h after placebo or UDCA 
administration. Plasma was separated within 30 minutes and stored at ?70 °C until analysis. 
 
3. Genotyping 
 
Genomic DNA was extracted from whole blood EDTA samples using standard methods 
(QIAamp Blood DNA Mini Kit, Qiagen, Hilden, Germany). Genotyping for six tagging SNPs 
of CYP7A1 (rs3808607, rs10957057, rs11786580, rs10504255, rs8192879, and rs1023652), 
two SLCO1B1 SNPs (c.521T>C, rs4149056 and c.388A>G, rs2306283), and also the uridine 
diphosphate-glucuronosyltransferase 1A1 (UGT1A1)*28 (rs8175347) allele were performed 
by Taqman® allelic discrimination methods as described previously (Pasanen et al. 2006b; 
Ehmer et  al. 2008).  Polymerase  chain  reactions  (PCRs)  were  carried  out  in  an  Applied  
Biosystems 7300 Real-Time PCR System or 2720 Thermal Cycler (Applied Biosystems, 
Foster  City,  CA,  USA).  Pre-  and  post-PCR  fluorescence  measurements  and  genotype  calls  
were performed using the 7300 Real-Time PCR System. PCR cycling conditions were set as 
follows: 1 cycle at 95 ºC for 10 minutes, followed by 40 cycles of melting at 95 ºC for 15 
seconds, and annealing and extending at 60 ºC for 1 minute. 
 
4. HPLC-MS/MS analyses 
 
4.1 Analysis of bile acid  
 
Firstly, to obtain bile acid-free plasma as a biological matrix for method validation, pooled 
drug-free human plasma was mixed and shaken with activated charcoal overnight to remove 
endogenous bile acids.  
 
Sample preparation was carried out by SPE extraction with C18 Bond Elut cartridges (Varian, 
Palo  Alto,  California,  USA).  Plasma  samples  (500  µl)  were  mixed  with  1.3  ml  of  0.05%  
formic acid and deuterium or 13C labeled internal standards. The mixture was then loaded 
onto the preconditioned extraction cartridges. Followed by wash with water and 5% 
methanol, the bile acids were eluted out with methanol and acetonitrile using gravity. The 
samples were evaporated at 60?C under a nitrogen stream. The residue was dissolved in 100 
µl  of  60%  methanol,  upon  which  the  sample  was  centrifuged  at  10000  RCF  and  4ºC  for  1  
minute. Fifteen µl of supernatant was injected into the HPLC-MS/MS system for analysis. 
 
The chromatographic system consisted of an Agilent 1100 series HPLC system from Agilent 
Technologies (Waldbronn, Germany). Chromatographic separation was achieved on an 
Atlantis®T3 column (2.1×100 mm, 3 µm) (Waters Corp., Milford, MA, USA), which was 
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protected by a 10 mm Atlantis®T3 guard cartridge (Waters Corp.). The mobile phase 
comprised (A) 10 mmol/l ammonium acetate and 0.005% formic acid in water and (B) 10 
mmol/l ammonium acetate and 0.005% formic acid in methanol. The eluents were set to 40% 
A during the first 2 minutes, after which the proportion was changed to 5% A in 13 minutes 
and maintained for 4.3 minutes. At 19.3 minutes, the proportion was changed back to 40% A 
within 0.1 minute, followed by 9.9 minutes of equilibration. The flow rate was set to 200 
µl/min.  
 
Mass spectra were obtained by an Applied Biosystems SCIEX API2000 mass spectrometer 
(Sciex Division of MDS, Toronto, Ontario, Canada) coupled with a TurboIonSpray interface 
operated in the negative ion mode. The MRM mode was chosen to acquire the quantitative 
data. The ion source temperature was set at 300?C.  Nitrogen  was  used  as  curtain  gas  and  
collision gas and set at 25 psi and 9 psi, respectively. The ion spray voltage was set at -4000 
V.  The  interface  heater  was  kept  on.  The  whole  chromatographic  run  was  divided  into  four  
periods. The ion transitions were mass-to-charge ratio (m/z) 391.1 to m/z 391.1 for UDCA, 
CDCA  and  DCA,  m/z 448.1 to m/z 448.1 for GUDCA, glycochenodeoxycholic acid 
(GCDCA) and GDCA, m/z 498.2 to m/z 79.9 for TUDCA, taurochenodeoxycholic acid 
(TCDCA) and taurodeoxycholic acid (TDCA), m/z 407.1 to m/z 407.1 for CA, m/z 464.2 to 
m/z 464.2 for GCA, m/z 514.2 to m/z 514.2 for TCA, m/z 375 to m/z 375 for LCA, m/z 432.1 
to m/z 73.8 for GLCA, m/z 482.2 to m/z 79.9 for taurolithocholic acid (TLCA), m/z 503.4 to 
m/z 79.9 for TUDCA-d5, m/z 465.2 to m/z 74.9  for  GCA-13C, m/z 502.1 to m/z 79.9 for 
TCDCA-d4, m/z 518.2 to m/z 518.2 for TCA-d4 and m/z 395.2 to m/z 395.2  for  CDCA-d4. 
Data were acquired with Analyst software, version 1.4. 
 
4.2 HPLC-MS/MS method validation  
 
To validate the HPLC-MS/MS method for the determination of bile acids in human plasma, 
the accuracy, precision, linearity, stability and extraction recovery of SPE cartridges was 
investigated according to the FDA (Food and Drug Administration) guidance for 
bioanalytical method validation (FDA, 2001). Moreover, the matrix effect of activated 
charcoal-purified plasma was compared with that of real plasma without charcoal 
purification.  
 
4.3 Analysis of 7?-hydroxy-4-cholesten-3-one  
 
Plasma samples of 500 µl were mixed with 1400 µl of 1% formic acid in acetonitrile and 100 
mg ammonium sulphate. The mixture was vortexed for 1 minute and centrifuged at 18 000 
RCF for 2 minutes. Then, 1300 µl acetonitrile supernatant was loaded onto 30 mg 
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HybridSPETM-Precipitation SPE tubes from Supelco (Bellefonte, PA, USA). The resulting 
eluent was dried at 50 °C under a nitrogen stream. The residue was dissolved in 20 µl of 
hexane-2-propanol (95:5, v/v) and 10 µl of the sample was injected into the HPLC-MS/MS 
system. 
 
The chromatographic separation was performed on a Waters Spherisorb®Silica column 
(4.6×100 mm, 3 µm) (Waters Corp.). The mobile phase consisted of hexane-2-propanol 
(95:5, v/v) and was used at a flow rate of 1 ml/min. Mass spectra were also obtained using an 
Applied Biosystems SCIEX API2000 mass spectrometer (Sciex Division of MDS) equipped 
with an APCI interface operated in positive ion mode. The ion transition was m/z 401.7 to m/z 
117.0 for 7?-hydroxy-4-cholesten-3-one. The limit of quantification was 5 nmol/l and 
between-day coefficients of variation were 8.45% at 15 nmol/l, 13.28% at 75 nmol/l and 
12.52% at 300 nmol/l (n = 6). 
 
4.4 Analysis of plasma total cholesterol 
 
Plasma samples of 50 µl were mixed with 150 µl of an aqueous potassium hydroxide solution 
(8.9 mol/l), 1 ml of ethanol and 100 µl of internal standard solution (stigmasterol, 2 mg/ml). 
The mixture was incubated in a water bath at 60 ºC for 2 hours to achieve complete 
saponification of the plasma. After hydrolysis, 2 ml of cyclohexane was added to the mixture. 
After being vortexed for 1 minute and centrifuged at 3000 RCF for 3 minutes, 1 ml of the 
cyclohexane phase was transferred to a clean glass tube and dried at 40 °C under a nitrogen 
stream. The residue was reconstituted with 1 ml of hexane-2-propanol (95:5, v/v) and 10 µl 
of the sample was injected to the HPLC-MS/MS system. 
 
The determination of cholesterol shared the same chromatographic and mass spectrometer 
conditions as 7?-hydroxy-4-cholesten-3-one, except that the ion transitions were m/z 369.3 to 
m/z 147.2 for cholesterol and m/z 395.2 to m/z 255.1 for stigmasterol. The limit of 
quantification was 0.2 mmol/l and between-day coefficients of variation at 0.6 mmol/l and 5 
mmol/l were both below 3% (n = 6). 
 
4.5 Determination of plasma bilirubin concentrations 
 
Plasma total and conjugated bilirubin concentrations were determined using a colorimetric 
diazo method (Total Bilirubin liquid and Direct bilirubin kits, Roche Diagnostics GmbH, 
Mannheim, Germany) on a Roche Hitachi MODULAR system (Hitachi Ltd., Tokyo, Japan). 
Unconjugated bilirubin was calculated by subtracting the conjugated bilirubin concentration 
from the total bilirubin concentration. 
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5. Ethical considerations 
 
All study protocols were approved by the Coordinating Ethics Committee of the Helsinki and 
Uusimaa Hospital District. The volunteers had given their written consent before 
participating in the studies.  
 
6. Pharmacokinetic analysis 
 
In Study IV, the pharmacokinetics of UDCA were characterized by the peak plasma 
concentration (Cmax), time to Cmax (tmax), and areas under the plasma concentration–time 
curve from 0 to 12 h (AUC0-12)  and  0  to  24  h  (AUC0-24). The elimination half-life (t??2) of 
UDCA could not be determined because of rebound increases after 9 h. Pharmacokinetic 
parameters were calculated with a non-compartmental model using the software MK-Model, 
version 5.0 (Biosoft, Cambridge, UK). The Cmax and tmax values were taken directly from the 
original data. The pharmacokinetics of the GUDCA and TUDCA metabolites of UDCA, and 
the diurnal profiles of endogenous bile acids were characterized by AUC0-24. The diurnal 
profiles of the bile acid synthesis marker 7?-hydroxy-4-cholesten-3-one and its ratio to 
cholesterol were characterized by their incremental AUC0-24. The AUC values of UDCA were 
calculated by a combination of the linear and log-linear trapezoidal rule, and the AUC0-24 of 
other bile acids and 7?-hydroxy-4-cholesten-3-one was calculated by the linear trapezoidal 
rule.  
 
7. Statistical analysis 
 
Statistical analyses were performed using SPSS 15.0 or 17.0 (SPSS, Chicago, IL, USA). In 
Studies II and III, for the subjects with more than one measurement, the mean value of all the 
measurements was used for statistical analysis. If a concentration was below the limit of 
quantification, the value was replaced with half of the limit of quantification to minimize the 
error in estimating mean values. Total bile acid is defined as the sum of the all measured bile 
acids. Statistical comparisons of the bile acid concentrations between subjects differing in 
gender or genotype were carried out with analysis of variance (ANOVA) and a priori 
pairwise testing with Fisher’s LSD method. In study II,  the equality of group variances was 
tested with the Levene statistic, and the compatibility of the residuals with a normal 
distribution was assessed using the Shapiro-Wilk test. In case of unequal variances or 
unsatisfactory distribution of the residuals, the data were logarithmically transformed before 
analysis, which corrected the deviances in all cases. Logarithmically transformed bile acid 
synthesis marker and bilirubin data were analyzed with ANOVA and pairwise testing with 
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Fisher’s LSD method, adjusting for the UGT1A1 genotype for bilirubin data. In study III, all 
the data were logarithmically transformed before analysis. Statistical comparisons of the bile 
acid variables between the genders were carried out with ANOVA. The effects of SLCO1B1 
and CYP7A1 genotypes on bile acid variables were investigated using two-way ANOVA with 
the  genotype  and  gender  as  between-subjects  factors.  Pairwise  testing  was  carried  out  with  
Fisher’s  LSD  method.  Intra-individual  variability  was  estimated  with  the  geometric  
coefficient of variation. In study IV, all the data except tmax and incremental AUC values were 
logarithmically transformed before statistical analysis. Statistical comparisons between the 
SLCO1B1 genotypes were performed using ANOVA, with body weight and gender as 
covariates, as appropriate, and a priori pairwise comparisons between the genotypes with 
Fisher’s least significant difference method. Differences between the placebo and UDCA 
phases were analyzed using repeated measures ANOVA. The tmax data were analyzed with the 
Kruskal–Wallis  test.  Differences  were  considered  statistically  significant  when  P < 0.05 for 
all  the  studies.  For  Study  III,  Bonferroni-corrected P-value thresholds were also calculated 
considering multiple testing. 
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RESULTS 
 
1. HPLC-MS/MS method for the determination of bile acids in human plasma 
 
Purification of normal human plasma using activated charcoal removed 99.99% (calculated 
from total peak areas) of endogenous bile acids (Figure 7). Further comparison of the matrix 
effect of bile acid-free plasma with that of real plasma revealed no significant difference in 
the matrix effect between charcoal-purified plasma and untreated plasma.  
 
Validation results showed a good linearity over a calibration curve range of 0.005–5 µmol/l 
for all the bile acids. The limits of detection (LODs) and limits of quantification (LOQs) were 
similar or lower than the previously reported values. Good intra- and inter-day accuracy was 
obtained for all the bile acids studied, as indicated by the ranges of 94.0–114.8% and 96.9–
113.5% for intra-day and inter-day, respectively. Coefficient of variation (CV) values, 
indicating method precision, were between 1.6 and 9.8% for intra-day analysis, and between 
1.5  and  9.8%  for  inter-day  analysis.  High  recoveries  of  the  SPE  extraction  procedure  were  
observed for all the bile acids, with the average value of 93.54%. Tests for bile acid stability 
during sample storage indicated that the bile acids were stable in plasma for at least 2 months 
at -70 ?C or -20 ?C.  
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Figure 7. Chromatograms of pooled human plasma samples prior to (A) and after (B) the 
removal of endogenous bile acids using activated charcoal. 
 
2. Effects of gender on the fasting plasma concentrations of bile acids and the bile acid 
synthesis marker 
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In Study III, the fasting plasma concentrations of several individual bile acids and total bile 
acids were significantly affected by gender. The geometric mean plasma concentrations of 
CDCA and GCDCA were 98% (P < 0.001) and 61% (P = 0.001) higher, respectively, in men 
than in women. Similarly, the geometric mean concentrations of UDCA and GUDCA, were 
111% (P = 0.001) and 98% (P < 0.001) higher, respectively, in men than in women. 
Furthermore, the mean concentration of total bile acids was 51% higher in men than in 
women (P = 0.001). Even after Bonferroni correction for multiple testing, the concentrations 
of  these  four  individual  bile  acids  and  of  total  bile  acids  still  significantly  differed  between 
the genders. Less significant differences (P < 0.05) were also seen in CA, DCA, and GDCA. 
Specifically, the geometric mean concentrations of CA, DCA, and GDCA were 86%, 37%, 
and 40% higher, respectively, in men than in women. Nevertheless, there were no significant 
gender differences in the plasma 7?-hydroxy-4-cholesten-3-one concentration, the 7?-
hydroxy-4-cholesten-3-one to cholesterol ratio, or total plasma cholesterol 
 
3. Effects of SLCO1B1 polymorphism on the fasting plasma concentrations of bile acids 
and the bile acid synthesis marker 
 
In Study II, the fasting plasma concentrations of seven endogenous bile acids were 
significantly associated with the SLCO1B1 genetic  polymorphism.  The  mean  plasma  
concentrations  of  UDCA,  GUDCA,  CDCA,  and  GCDCA  were  lower  (P < 0.05) in 
individuals with the SLCO1B1*1B/*1B genotype than in those with the *1A/*1A, c.521TC, or 
c.521CC genotypes. Moreover, the mean concentration of TUDCA in SLCO1B1 c.521TC 
participants was about 2.2-fold that in *1B/*1B participants (P = 0.036). Similarly, the mean 
concentrations of TCDCA in c.521CC or c.521TC participants were approximately 2.1-fold 
that in *1B/*1B participants (P < 0.05). A smaller but significant difference was seen for CA, 
which was about 30% higher in subjects with the SLCO1B1*1A/*1A or c.521CC genotype 
than in those with the *1B/*1B genotype (P < 0.05). SLCO1B1 genetic polymorphism also 
significantly affected the fasting plasma concentration of the bile acid synthesis marker, 7?-
hydroxy-4-cholesten-3-one. Specifically, the estimated marginal mean concentration of 
plasma 7?-hydroxy-4-cholesten-3-one in subjects with the SLCO1B1*1A/*1A genotype was 
72% or 50% higher than in those with the SLCO1B1*1B/*1B or c.521TC genotype, 
respectively (P < 0.05). Consistently, the 7?-hydroxy-4-cholesten-3-one to cholesterol ratio in 
the SLCO1B1*1A/*1A participants was 62% or 45% higher than in the SLCO1B1*1B/*1B or 
c.521TC participants, respectively (P < 0.05). However, these findings were not replicated in 
Study III with a larger sample size (143), in which no associations were observed between the 
SLCO1B1 genotype and any of the measured bile acids or 7?-hydroxy-4-cholesten-3-one. 
Furthermore, during the placebo phase of Study IV, no association was found between 
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SLCO1B1 polymorphism and the diurnal profile of any bile acid, 7?-hydroxy-4-cholesten-3-
one, or the 7?-hydroxy-4-cholesten-3-one to cholesterol ratio, as indicated by their 
corresponding AUC0-24 or incremental AUC0-24. In Study III, the geometric mean 
concentration of total plasma cholesterol was 13–19% (P < 0.05) lower in individuals with 
the SLCO1B1 c.521CC  genotype  than  in  those  with  the  *1A/*1A, *1A/*1B or c.521TC 
genotype, respectively, but the differences were not significant after correction for multiple 
testing. 
 
4. Effects of SLCO1B1 polymorphism on UDCA pharmacokinetics 
 
In Study IV, the SLCO1B1 genotype had no significant effect on the pharmacokinetics of 
UDCA, GUDCA or TUDCA (Figures 8 and 9). Moreover, after UDCA administration, there 
was no significant difference in the AUC0-24 of 13 other endogenous bile acids, or the 
incremental AUC0-24 of 7?-hydroxy-4-cholesten-3-one, or the 7?-hydroxy-4-cholesten-3-one 
to cholesterol ratio among the different SLCO1B1 genotypes.  
 
As expected, UDCA administration raised the geometric mean AUC0-24 of UDCA, GUDCA, 
TUDCA and total bile acids by 14.8-fold (P < 0.001), 6.5-fold (P < 0.001), 3.5-fold (P < 
0.001) and 1.5-fold (P < 0.001), respectively, compared to the placebo phase. Additionally, 
the geometric mean AUC0-24 of CA, GCA, GCDCA, and GDCA, were 1.5-fold (P = 0.017), 
1.2-fold % (P = 0.031), 1.1-fold (P = 0.026), and 1.2-fold (P = 0.037) higher, respectively 
during the UDCA phase than during the placebo phase. Nonetheless, there were no 
significant differences in the incremental AUC0-24 of 7?-hydroxy-4-cholesten-3-one or the 
??-hydroxy-4-cholesten-3-one to cholesterol ratio between the two phases. 
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Figure 8. Geometric mean Cmax, AUC0-12h, and AUC0-24h ratios of UDCA in subjects with the 
SLCO1B1 *1B/*1B genotype (n = 7), or *15/*15 or *5/*15 genotype (n = 5) vs. subjects with 
*1A/*1A genotype (n = 15) after a single 150-mg oral dose of UDCA. The error bars depict 
the 95% confidence intervals.   
 
Figure  9. Geometric mean AUC0-24h ratios  of  GUDCA  or  TUDCA  in  subjects  with  the 
SLCO1B1 *1B/*1B genotype (n = 7), or *15/*15 or *5/*15 genotype (n = 5) vs. subjects with 
the  *1A/*1A genotype (n = 15) after a single 150-mg oral dose of UDCA. The error bars 
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depict the 95% confidence intervals.   
 
5. Effects of CYP7A1 polymorphism on the fasting plasma concentrations of bile acids 
and the bile acid synthesis marker 
 
In Study III, the geometric mean plasma concentration of DCA in subjects with the 
rs8192879CT genotype was 53% higher than in those with the CC genotype (P = 0.005). The 
geometric mean plasma concentration of hyodeoxycholic acid (HDCA) was 34–41% 
(P < 0.05) lower in individuals with the rs1023652GG genotype than in those with the CG or 
CC  genotype.  Nevertheless,  after  Bonferroni  correction  for  multiple  testing,  none  of  the  
differences was statistically significant. Moreover, there was no association between the 
CYP7A1 SNPs  and  the  plasma  concentrations  of  total  cholesterol  or  the  bile  acid  synthesis  
marker, 7?-hydroxy-4-cholesten-3-one or the 7?-hydroxy-4-cholesten-3-one to cholesterol 
ratio. 
 
6. Effects of SLCO1B1 polymorphism on plasma bilirubin 
 
In Study II, after adjusting for the UGT1A1 genotype, the estimated marginal mean plasma 
concentration of unconjugated bilirubin in individuals with the SLCO1B1*1B/*1B genotype 
was 57–82% (P <  0.05),  higher  than  in  those  with  the  c.521TC  (P < 0.01), *1A/*1A (P < 
0.01) or c.521CC genotype. Similar associations were also observed for the total plasma 
bilirubin, whereas conjugated bilirubin was only significantly higher in the 
SLCO1B1*1B/*1B than in the *1A/*1A group. Significantly elevated plasma concentrations 
of both unconjugated and conjugated bilirubin were seen in those individuals carrying the 
UGT1A1*28 allele. 
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DISCUSSION 
1. Methodological considerations  
 
1.1 HPLC-MS/MS method for the determination of bile acids 
 
Human plasma or  serum always  contains  a  certain  amount  of  endogenous  bile  acids,  which  
cannot be distinguished from the reference standards added when preparing the calibration 
standard and quality control samples. In some published methods for the determination of 
bile acids, pooled serum or plasma has been employed to prepare calibration standards and 
quality control samples (Tagliacozzi et al. 2003; Burkard et al. 2005; Ye et al. 2007). Thus, 
the exact concentrations of these calibration standard and quality control samples cannot be 
known, and the calculation of LOD and LOQ has been based on the formula: LOD = 3.3?/S 
and LOQ = 10?/S. S is the slope of the calibration curve, and ? is the standard deviation of 
the peak area for each analyte. Since the endogenous bile acid concentrations of pooled 
plasma  or  serum  cannot  be  identical  in  different  laboratories,  LOD  and  LOQ  values  might  
differ greatly due to the varying ? values, even if other conditions are similar.  
 
In some other papers, water has been used to replace pooled plasma or serum to prepare the 
calibration standards (Bentayeb et al. 2008; Bobeldijk et al. 2008). Nevertheless, this simple 
approach does not allow investigation of the matrix effect of other endogenous compounds 
existing in plasma or serum. The matrix effect may not only affect the MS determination by 
enhancing or suppressing bile acid signals, but also influence the SPE extraction procedure. 
Therefore,  bile  acid-free  plasma,  which  still  retains  most  properties  of  normal  plasma,  was  
highly desirable in this study. Some articles have reported the application of activated 
charcoal in removing bile acids and other amphiphilic compounds from the protein matrix.  
 
Thus, activated charcoal was investigated in our study to remove the endogenous bile acids 
from the pooled plasma. Activated charcoal has previously been used in other applications as 
an adsorbent of amphiphilic compounds such as bile acids from the protein matrix. For 
example, a bioartificial liver comprising a charcoal column and porcine hepatocytes was able 
to remove extra serum bile acids in patients with dysfunctional liver (Pazzi et al. 2002). We 
finally demonstrated that activated charcoal could extract the endogenous bile acids from 
human plasma (Figure 7).  
 
Furthermore, the matrix effect of charcoal-purified plasma was compared with three different 
lots of real, untreated plasma. No significant difference was observed in matrix effect 
between the charcoal-purified plasma and real plasma. These data indicate that the charcoal 
purification  process  did  not  change  the  properties  of  bile  acid-free  plasma  as  a  biological  
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matrix for the preparation of calibration standards and quality controls. This type of bile acid-
free plasma is a suitable blank matrix for method validation in bile acid analysis.  
 
In conclusion, this method includes a direct SPE extraction procedure followed by HPLC-
MS/MS detection. The validation results indicate that it is a robust, sensitive and simple 
method to determine the bile acid concentrations in human plasma.  
 
1.2 Clinical studies 
 
Studies II and III were retrospective studies including 65 and 143 subjects, respectively. The 
participants  were  all  young  healthy  Caucasians  with  normal  levels  of  activity.  The  fasting  
blood samples were drawn in the morning after an overnight fast of at least 8 hours. The use 
of all drugs, including oral contraceptive steroids, was prohibited for 1 week, the use of 
grapefruit products for 3 days, and alcohol consumption for 1 day before blood collection. 
However, the last meal was not a standardized one, and the overnight fast was not controlled 
in in-house conditions. Moreover, caffeine use and cholesterol levels in the everyday diet 
were not controlled. Study II was a hypothesis-generating study, while Study III aimed to test 
the findings of Study II with a larger sample size. The data from Study II were not included 
with Study III for statistical analysis for two reasons. Firstly, some statistically significant 
differences were observed between Studies II and III with respect to the demographic data 
and bile acid concentrations. The subjects in Study II were slightly (by 1 year) younger than 
those in Study III. UDCA and GUDCA were higher and LCA was lower in Study II than in 
Study III. Secondly, the storage time of plasma samples (mean ± SD: 2.25 ± 0.56 years) in 
Study II was considerably longer than that (0.45 ± 0.30 years) in Study III.     
 
Study IV was a prospective genotype panel study with 27 healthy volunteers harbouring 
different SLCO1B1 genotypes, including 15 with the *1A/*1A genotype, 7 with the *1B/*1B 
genotype, and 5 with the *15/*15 or *5/*15 genotype. The number of subjects in each 
genotype group was estimated to be sufficient to detect possible clinically meaningful effects 
of SLCO1B1 genetic variations on the pharmacokinetics of UDCA (about 50% lower or 
higher AUC in subjects with the *1B/*1B or *15/*15 (*5/*15) genotypes than in those with 
the *1A/*1A genotype), with a power higher than 80% and an ?-level of 0.05. This a priori 
power analysis was conducted with the software G*Power 2 (Erdfelder 1996). A fixed-order 
crossover design with two phases was used in Study IV. Thus, participants served as their 
own controls during the placebo and UDCA phase, enabling an investigation of the effects of 
UDCA administration on endogenous bile acids and the bile acid synthesis marker. 
Considering food-stimulated bile secretion, a standardized meal and snack was provided, and 
the food intake schedule was strictly controlled in the two phases of Study IV.    
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2. Effects of gender on the fasting plasma concentrations of bile acids  
 
In Study III, the mean fasting plasma concentrations of several individual bile acids, 
including CDCA, CA, UDCA, DCA, GCDCA, GUDCA and GDCA, were 37–111% higher 
in  88  men than  in  55  women.  Consequently,  the  mean concentration  of  total  bile  acids  was  
51% higher in the men than in the women. Consistent with our findings, a recently published 
study in 200 healthy individuals reported that the fasting serum levels of CDCA and CA were 
significantly higher in men than in women (Trottier et al. 2011). These data were supported 
by a previous observation that men have significantly larger CDCA and total bile acid pools 
than women (Bennion et al. 1978).  
 
It appears that the gender differences do not arise from the classical pathway of bile acid 
synthesis, because no significant differences between men and women were seen in plasma 
concentrations of 7?-hydroxy-4-cholesten-3-one or the 7?-hydroxy-4-cholesten-3-one to 
cholesterol  ratio,  which  reflect  the  activity  of  the  rate-limiting  CYP7A1  enzyme  in  the  
classical pathway. Conversely, the plasma concentration of 27-hydroxycholesterol, an 
intermediate in the alternative (acidic) bile acid synthesis pathway, has been found to be 
higher in men than in women (Dzeletovic et al. 1995). This suggests that the gender 
differences in fasting plasma bile acids might be attributed to gender differences in the 
activity of the alternative pathway of bile acid production. 
 
3. Effect of SLCO1B1 polymorphism on the fasting plasma concentrations of bile acids  
 
In Study II, SLCO1B1 genetic polymorphism seemed to affect the fasting plasma 
concentrations of several bile acids, including CDCA, UDCA, GCDCA, GUDCA, TCDCA, 
TUDCA and CA. The concentrations of these bile acids were lowest in subjects with the 
SLCO1B1*1B/*1B genotype and highest in those with the SLCO1B1 c.521TC or c.521CC 
genotype. Of these bile acids, in vitro studies  have  shown  that  GUDCA,  TUDCA,  CA  and  
CDCA are transported by OATP1B1 (Table 1) (Cui et al. 2001; Yamaguchi et al. 2006; 
Maeda et al. 2006a). UDCA was not transported by OATP1B1 in one in vitro study using 
transporter-overexpressing HEK293 cells (Maeda et al. 2006a), whereas in another in vitro 
study, a fluorescently labelled UDCA derivative was transported by OATP1B1 and OATP1B3 
with a low affinity (Yamaguchi et al. 2006). No in vitro data  are  available  on  the  role  of  
OATP1B1  in  the  transport  of  GCDCA  and  TCDCA.  The  reduced  plasma  concentrations  of  
these bile acids associated with the SLCO1B1*1B/*1B genotype are consistent with enhanced 
hepatic uptake by OATP1B1 during their enterohepatic recycling.  
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Clinical data have indicated that the SLCO1B1 *1B/*1B genotype is associated with 
increased transport activity for some OATP1B1 substrates, such as pravastatin and 
repaglinide, as reflected by their lower systemic exposure compared with the 
SLCO1B1*1A/*1A genotype (Maeda et al. 2006b; Kalliokoski et al. 2008a). Nevertheless, 
unlike the *5 or *15 haplotypes, the effects of the SLCO1B1*1B haplotype may be substrate 
specific (Niemi et al. 2011).  For example,  the SLCO1B1*1B haplotype has been reported to 
have no effect on the pharmacokinetics of rosuvastatin (Lee et al. 2005; Choi et al. 2008). 
Similarly, the SLCO1B1*1B variant has either decreased, increased or had no effect on 
OATP1B1 activity in vitro (Tirona et  al. 2001; Tirona et al. 2003; Kameyama et al. 2005; 
Nozawa et al. 2005, Kalliokoski et al. 2010).  
 
However, in Study III with a large sample size (143 participants vs. 65 participants in Study 
II), SLCO1B1 polymorphism had no effect on the fasting plasma concentrations of bile acids. 
Although there were more subjects in Study III, there were fewer measurements for each 
individual (median: 1) than in Study II (median: 5). High intraindividual variability in the 
fasting plasma levels of bile acids is a possible explanation for the discrepancy between 
Studies II and III. In Study IV, further investigation including 27 individuals was carried out 
into the effects of SLCO1B1 polymorphism on the diurnal profiles of 16 endogenous bile 
acids and also the bile acid synthesis marker. Similarly to Study III, SLCO1B1 polymorphism 
had no significant effect on bile acid profiles. Interestingly, in Study III, total plasma 
cholesterol concentration was lower in individuals with the SLCO1B1 c.521CC genotype than 
in  those  with  *1A/*1A, c.521TC, or *1A/*1B genotype. This would be consistent with 
reduced hepatic uptake of bile acids associated with the c.521CC genotype, because the 
hepatocellular conversion of cholesterol into bile acids is regulated through negative 
feedback. However, testing of this hypothesis requires a larger population. 
 
Based on evidence from Studies II, III and IV, it might be concluded that compared to gender, 
the possible effect of SLCO1B1 polymorphism on the fasting plasma concentrations of 
individual bile acids is much less prominent. The hypothesis raised in Study II was not 
proven in Studies III and IV.    
 
4. Effect of SLCO1B1 polymorphism on the bile acid synthesis marker 
 
In Study II, the concentration of the bile acid synthesis marker was reduced in individuals 
with the SLCO1B1*1B/*1B genotype  as  compared  with  those  with  the  SLCO1B1*1A/*1A 
genotype. This is in accordance with the hypothesis that the SLCO1B1*1B/*1B genotype is 
associated with enhanced hepatic uptake of certain bile acids, because bile acid production 
from cholesterol is regulated by hepatocellular levels of bile acids via a negative-feedback 
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loop (Vlahcevic et al. 1991). However, in Studies III and IV, SLCO1B1 polymorphism had no 
effect on fasting plasma concentrations or incremental AUC0-24h of the bile acid synthesis 
marker. Taken together, it appears that SLCO1B1 genetic polymorphism is unlikely to exert a 
significant influence on the bile acid synthesis marker.  
 
5. Effects of CYP7A1 polymorphism on the fasting plasma concentrations of bile acids 
and the bile acid synthesis marker 
 
Secondary hydrophobic bile acids, mostly DCA and LCA, have long been implicated in the 
pathogenesis of colon cancer (Degirolamo et al. 2011). Both animal and in vitro studies have 
suggested that DCA promotes the carcinogenesis of colorectal cancer (Reddy et  al. 1976; 
Milovic et al. 2002). A case-control study demonstrated that serum concentrations of DCA 
were significantly higher in men with colorectal adenomas than in healthy controls 
(Bayerdorffer et al. 1993). Being the rate-limiting enzyme of bile acid production, CYP7A1 
plays an important role in bile acid biosynthesis. Therefore, possible associations between 
genetic variations in CYP7A1 and the incidence or risk of colon cancer have previously been 
investigated. Such an association has been observed in Japanese colorectal cancer patients, 
who have a low frequency of the CYP7A1 g.-203CC genotype compared to healthy controls 
(Hagiwara et al. 2005).  
 
In Study III, we investigated the effects of several CYP7A1 haplotype-tagging SNPs, 
including g.-203A>C, on the fasting plasma concentrations of 16 bile acids. Although some 
bile acids seemed to be affected by certain CYP7A1 SNPs, generally no consistent association 
was seen between CYP7A1 genetic polymorphism and the fasting plasma concentrations of 
individual bile acids. This suggests that common genetic variations in CYP7A1 are  not  
important determinants of individual bile acid concentrations in healthy individuals. 
 
The effects of the CYP7A1 g.-203A>C SNP on plasma cholesterol concentrations have been 
investigated  in  a  number  of  studies,  some  of  which  have  identified  an  association  between  
this SNP and LDL-cholesterol concentrations (Wang et  al. 1998; Couture et  al. 1999). 
However, such findings have not been replicated in other studies (Hofman et  al. 2004; 
Abrahamsson et al. 2005; Hofman et al. 2005). The inconsistency may be due to inadequate 
sample sizes (Abrahamsson et al. 2005), while it is also possible that the effects g.-203A>C 
SNP on plasma lipids are population specific (Hegele et al. 2001).  
 
??-Hydroxy-4-cholesten-3-one is an intermediate product of bile acid synthesis, closely 
reflecting the activity of CYP7A1. Plasma levels of this bile acid synthesis marker were not 
affected by the CYP7A1 g.-203A>C SNP in 30 gallstone patients (Abrahamsson et al. 2005) 
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or in another study including 66 healthy subjects (Lenicek et al. 2008). Study III confirmed 
no impact of the CYP7A1 g.-203A>C SNP on CYP7A1 activity, as measured by the plasma 
concentrations of 7?-hydroxy-4-cholesten-3-one and the 7?-hydroxy-4-cholesten-3-one to 
cholesterol ratio, with a larger sample size including 143 healthy individuals. Furthermore, 
none of the other five CYP7A1 haplotype-tagging SNPs genotyped in Study III was 
associated with this bile acid synthesis marker. Interestingly, after ileal resection leading to 
bile acid malabsorption, patients homozygous for the g.-203A allele had a two-fold higher 
??-hydroxy-4-cholesten-3-one to cholesterol ratio than g.-203CC homozygotes (Lenicek et 
al. 2008). Thus, these data suggest that the g.-203A>C SNP may affect CYP7A1 activity 
under certain pathological conditions, rather than a normal physiological condition.  
 
In conclusion, the common genetic polymorphisms of CYP7A1 have no significant influence 
on the activity of CYP7A1 or plasma concentrations of individual bile acids under normal 
physiological conditions. 
 
6. Effects of SLCO1B1 polymorphism on UDCA pharmacokinetics 
 
In  Study  II,  it  was  found  that  the  fasting  plasma  concentrations  of  UDCA  as  well  as  its  
glycine and taurine conjugates were affected by SLCO1B1 polymorphism. This finding may 
have clinical implications because natural UDCA is also used as a therapeutic drug. In vitro 
experiments employing human hepatocytes have demonstrated that 51% of the overall 
hepatocellular uptake of UDCA relies on a sodium independent mechanism, which is mainly 
mediated by OATPs. The corresponding values for TUDCA and GUDCA are 45% and 79%, 
respectively. GUDCA and TUDCA were identified to be substrates of OATP1B1 and 
OATP1B3 in transport assays using transporter-expressing HEK293 cells, while UDCA was 
not (Maeda et  al. 2006a). Moreover, GUDCA was suggested to be the effective form of 
UDCA because only a negligible amount of UDCA is found in the bile after UDCA ingestion 
(Beuers 2006), and GUDCA concentration in portal vein is significantly higher than that of 
UDCA in gallstone patients receiving UDCA therapy (Ewerth et  al. 1985). Therefore, the 
pharmacokinetics of GUDCA may be an important factor affecting UDCA efficacy. Based on 
these data, Study IV was planned to investigate the effects of SLCO1B1 genetic variations on 
the pharmacokinetics of exogenously administered UDCA. Nevertheless, in Study IV, 
SLCO1B1 polymorphism had no significant effect on the pharmacokinetic variables of 
UDCA or its conjugates, or the AUC0-24 of other endogenous bile acids and the bile acid 
synthesis marker after a single oral dose of 150 mg UDCA.  
 
Taken together with in vitro data and the results from Study III, the results indicate that 
UDCA is unlikely to be transported by OATP1B1 in vivo.  Moreover,  it  is  also possible that 
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passive diffusion contributes more to the hepatic extraction of orally administered UDCA 
than active transport. Experiments in rat hepatocytes indicate that both passive diffusion and 
active transport are involved in the hepatocellular uptake of UDCA (Schwarz et al. 1975; 
Anwer and Hegner 1978; Inoue et al. 1982; Van Dyke et al. 1982; Duffy et  al. 1983). The 
concentrations  of  UDCA  and  its  conjugates  in  plasma  are  far  below  those  in  hepatocytes  
under fasting conditions without exogenous UDCA intake, and thus OATP and NTCP-
mediated active influx are favoured over the concentration gradient. However, after ingestion 
of exogenous UDCA, the plasma-to-hepatocyte concentration ratio is markedly elevated, 
resulting  in  a  larger  contribution  of  passive  diffusion  to  UDCA  influx  into  the  liver.  In  
conclusion, OATP1B1-mediated hepatic uptake appears not to be a limiting step in the in vivo 
disposition of exogenously administered UDCA or its conjugates. 
 
Another  finding  of  Study  IV  is  that  a  single  oral  dose  of  UDCA  significantly  elevated  the  
plasma concentrations of several endogenous bile acids including CA, GCA, GCDCA and 
GDCA. This might be caused by competitive inhibition of bile acid influx transporters on the 
basolateral membrane and/or efflux transporters on the apical membrane of hepatocytes by 
high concentrations of UDCA and its conjugates. Further in vitro experiments are warranted 
to investigate the inhibitory potential of UDCA and its conjugates on bile acid transporters.     
   
7. Effect of SLCO1B1 polymorphism on plasma bilirubin 
 
In Study II, plasma unconjugated and total bilirubin concentrations were significantly higher 
in individuals with the SLCO1B1*1B/*1B genotype than in those with the other SLCO1B1 
genotypes. This is in contrast to a finding from healthy Chinese individuals that the serum 
unconjugated and total bilirubin concentrations were significantly lower in 
SLCO1B1*1B/*1B individuals than in *1B/*15 or *15/*15 individuals (Zhang et  al. 2007). 
One possible explanation for the discrepancy is that the results of this study were not adjusted 
for the UGT1A1*28 allele, as our study was. Another study in Japanese individuals also took 
the UGT1A1*28 allele into account, and identified a statistically non-significant trend 
towards lower bilirubin concentrations in carriers of the SLCO1B1*1B allele (Ieiri et al. 
2004). Similar to our results, there was a non-significant trend towards an increased total 
bilirubin concentration in European Americans having the SLCO1B1*1B/*1B genotype (Ho 
et al. 2007). However, compared to the large effect of the UGT1A1 genotype on the plasma 
concentrations of both conjugated and unconjugated bilirubin, also seen in previous studies 
(Lampe et  al. 1999), the SLCO1B1 genotype  seems  to  exert  a  relatively  small  effect  on  
fasting plasma levels of unconjugated bilirubin. This was strongly supported by a genome-
wide association meta-analysis showing that UGT1A1 polymorphism explains about 18.0% 
of the variation in total serum bilirubin levels, while the contribution of SLCO1B1 
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polymorphism is only 1.0% (Johnson et  al. 2009). Nevertheless, another GWAS study 
comprising 8841 Korean individuals found that the SLCO1B3 variant, not SLCO1B1, 
significantly influenced the serum bilirubin levels (Kang et al. 2010). 
 
8. Clinical implications  
 
Measurement of total bile acids in serum has been a routine test for the diagnosis of liver 
diseases, such as ICP. Nevertheless, the diagnostic value of total serum bile acids for ICP is 
limited due to the observation that total bile acids are also elevated during normal pregnancy 
(Sinakos and Lindor 2010). After comparing the longitudinal profiles of 15 individual bile 
acids in serum between ICP patients and normal controls, Tribe et al. suggested that TCA and 
TCDCA might be more useful biomarkers for the diagnosis of ICP (Tribe et al. 2010). Thus, 
the HPLC-MS/MS method developed in Study I has the potential to be implemented in 
clinical practice for better diagnostic purposes. 
 
Pharmacogenetics can only explain a fraction of the variability in drug responses. Recently, 
metabolomics has also been applied in predicting the response to drug treatment by mapping 
the metabolic pathway in the therapeutic response. A very recent metabolomics study 
(published during the reviewing of this thesis manuscript) found correlations between 
pretreatment plasma concentrations of secondary bile acids and the LDL-cholesterol response 
to simvastatin treatment, as well as the plasma levels of simvastatin acid (Kaddurah-Daouk et 
al. 2011). The authors suggested that such a correlation existed because simvastatin acid and 
bile acids share the same hepatic and intestinal transporters. Furthermore, in the same study, 
the fasting plasma concentrations of seven bile acids prior to simvastatin administration were 
associated with the c.521T>C SNP of the SLCO1B1 gene, whereas the c.388A>G SNP was 
not associated with the pretreatment plasma levels of individual bile acids. Studies II and III 
investigated the genetic factors possibly influencing the profiles of circulating individual bile 
acids, indicating that high intraindividual variability in the fasting plasma levels of bile acids 
must be carefully considered to avoid any conclusion by chance. 
 
Some drugs acting on bile acids behave differently between men and women. For example, 
the reduced serum concentrations of various bile acids and total bile acids caused by 
fenofibrate have only been observed in men (Trottier et al. 2011).  Similarly,  the  effective  
prevention of colorectal carcinoma by UDCA was only seen in men (Thompson et al. 2009). 
Therefore, gender differences in the levels of circulating bile acids might contribute to 
gender-related differences in the response to these drugs. Moreover, besides the well-known 
function of bile acids in dietary lipid absorption and cholesterol homeostasis, the important 
role of bile acids in endocrine signalling has recently been gaining increasing attention. For 
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example, bile acids can regulate cardiovascular function through their interaction with G-
protein-coupled receptors on the plasma membrane (Khurana et al. 2011). In addition, it has 
been reported that gender differences exist in the prognostic values of cardiovascular risk 
factors (Zhang et al. 2011). Thus, the gender difference in fasting plasma profiles of 
individual bile acids may present a clue for why women and men show quite different 
outcomes of cardiovascular diseases.  
 
Increasing evidence is emerging to support the important roles of bile acids in many 
physiological processes and the response to internal or external stimuli. Thus, there is a need 
to identify the factors contributing to the variability of circulating bile acid levels in the body. 
A complete understanding of these factors could help in evaluating the exact roles of bile 
acids in health and disease. Further studies are required to determine whether genetic 
differences are important determinants of interindividual variability in bile acid levels. The 
rapidly evolving genomics and metabolomics techniques may be useful to find such factors. 
Moreover, more mechanistic, in vitro studies are required to fully understand the roles of 
transporters and enzymes in bile acid homeostasis.   
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CONCLUSIONS 
 
Based on the results of Studies I-IV, the following conclusions can be made: 
 
Study I    A robust,  sensitive,  and simple method was developed to determine the bile acid 
concentrations in human plasma. We also described the preparation of bile acid-free plasma, 
making the validation of bile acid analysis straightforward and reproducible. This HPLC-
MS/MS method has been successfully applied in Studies II, III and IV.  
 
Studies II & III   Genetic polymorphism in SLCO1B1 appeared to significantly affect the 
fasting plasma bile acid profile and bile acid synthesis marker in Study II with a small group 
of healthy subjects, but these findings could not be replicated in Study III with a larger 
sample size. The inconsistency between Studies II and III might be explained by high 
intraindividual variability in the fasting plasma levels of bile acids. On the other hand, gender 
has a major effect on the fasting plasma concentrations of individual bile acids. In addition, 
common genetic variability in CYP7A1 has no major effect on the activity of CYP7A1, which 
was characterized by a bile acid synthesis marker, or plasma concentrations of individual bile 
acids under normal physiological conditions.  
 
Study IV Genetic polymorphism in the SLCO1B1 gene has no significant effect on the 
pharmacokinetics of UDCA or its conjugates in healthy volunteers, suggesting that OATP1B1 
does  not  play  a  clinically  important  role  in  the  disposition  of  a  therapeutic  dose  of  UDCA.  
Passive diffusion may be more important than active transport in the hepatic uptake of 
exogenously administered UDCA from portal blood.  
 
General  
In conclusion, these studies suggest that gender, but not SLCO1B1 or CYP7A1 
polymorphism, has a major effect on the fasting plasma concentrations of individual bile 
acids. Moreover, common genetic polymorphisms of CYP7A1 are unlikely to affect the 
activity of CYP7A1 under normal physiological conditions, and OATP1B1 does not seem to 
be important for the in vivo disposition of exogenously administered UDCA.        
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